Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Most founders think diligence happens in the obvious places.

The pitch meeting. The follow-up call. The data room. The financial model. The customer references the founder provides. The investor update. The partner meeting. The formal diligence process after a fund becomes serious.

All of that matters, but it is not the whole picture.

Investors do not only diligence the company through the materials the founder controls. They also diligence the company through the market. They speak to customers, former colleagues, advisors, operators, co-investors, sector experts, clinicians, executives, academics, founders, recruiters, strategic partners, and people who have seen the company from different angles.

Sometimes the founder knows those calls are happening. Sometimes they do not.

This is the reference call risk. It happens when the market is telling a story about the company before the founder realises diligence has already started. That story may reinforce the investment case. It may create doubt. It may explain why customers care. It may reveal that the product is harder to implement than the founder suggested. It may validate the founder’s reputation. It may surface concerns about execution, leadership, commercial maturity, science, adoption, or team quality.

Founders often underestimate this because they think diligence is linear. First meeting, second meeting, data room, formal references, investment committee. In reality, investor diligence is often happening around the process, not only inside it.

A fund may speak to someone who knows the buyer. A partner may message an operator in the space. An associate may call another founder who has sold into the same customer segment. A venture partner may know someone who worked with the founder before. A co-investor may have heard the company discussed in another round. A strategic may have seen the product in a pilot. A customer may have told someone the company is impressive, but not yet ready.

The market talks.

The question is whether the story it tells supports the story the founder is telling.

Subscribe now

Diligence does not wait for permission

Founders often assume that serious diligence begins only when an investor formally asks for references. That is not how many investors work. By the time a founder receives a detailed diligence request, the investor may already have spoken to several people around the market.

This is not always a bad thing. A strong market reputation can help the company. If customers speak highly of the product, if operators respect the founder, if former colleagues describe the founder as exceptional, if sector experts confirm the pain is real, and if other investors say the company has been thoughtful, the founder benefits from a story they did not have to push.

But the reverse is also true. If the informal market narrative is messy, investors may slow down before the founder understands why. They may ask more cautious questions. They may become harder to read. They may say they need more time. They may pass with polite language because the concern came from a conversation the founder never saw.

This is uncomfortable because founders like to believe they control the fundraising process. They control the deck. They control the narrative. They control the data room. They control which customer references are provided. They control the update cadence. They control what gets shared and when.

Informal diligence breaks that illusion.

Investors are trying to reduce uncertainty. If they can learn more about the company from people around the market, they will. That does not mean they are acting unfairly. It means they are doing their job. Early-stage investing often involves incomplete information, and investors use networks to test whether the founder’s version of reality matches what others are seeing.

The founder cannot control every reference call. But they can understand that the company is always creating references, whether intentional or not.

Your reputation is part of the data room

A data room contains documents. The market contains memory.

Founders often spend weeks polishing materials while ignoring the fact that many important people already have an opinion about the company. Customers remember how the team handled implementation. Advisors remember whether the founder listened or only collected names. Former employees remember whether the company was clear or chaotic. Co-investors remember whether updates were consistent. Operators remember whether the product solved a real problem or only sounded good in a pitch.

That memory becomes part of diligence.

This is why reputation is not a soft issue. It is not separate from the financing process. It influences investor trust, customer confidence, hiring, partnerships, and the willingness of others to help the company. A founder with a strong reputation can often move faster because the market gives them credibility before the meeting starts. A founder with a weak or unclear reputation may have to work harder because every claim needs more proof.

In health, this matters even more because the market is smaller than founders think. Specialists know each other. Clinicians speak to other clinicians. Investors compare notes. Strategic teams watch companies for years. People move between hospitals, pharma, venture funds, startups, universities, and advisory roles. A conversation in one corner of the market can reach another corner quickly.

That does not mean founders need to be paranoid. It means they need to be consistent. The story told in the deck should not be completely different from the story customers experience. The founder’s description of traction should not be dramatically stronger than what references would say. The partnership slide should not imply commitment where there is only exploration. The market access story should not depend on names that would not confirm the relationship.

When the external story and the market story diverge, diligence becomes harder.

Informal references test exaggeration

One of the reasons investors make reference calls is to test whether the founder is exaggerating. This does not always mean lying. More often, the concern is inflation.

A founder may call a customer conversation “traction.” The customer may describe it as early exploration. A founder may describe a pilot as highly engaged. The hospital may say the pilot is interesting, but not a priority. A founder may describe a strategic partner as excited. The corporate team may say they are watching the space but not moving yet. A founder may describe an advisor as deeply involved. The advisor may say they have only had two calls.

None of these gaps have to destroy the round, but they create doubt.

Investors understand that founders are optimistic. They expect some ambition in the story. But they become concerned when the founder’s version of reality is consistently ahead of what the market confirms. That gap makes the investor wonder what else may be overstated.

This is why precision matters. Founders should describe relationships, evidence, customer demand, pilots, partnerships, and investor interest accurately. It is better to say, “We are in early discussions with two hospital innovation teams,” than to imply those hospitals are already committed customers. It is better to say, “We have a clinical advisor who has helped us refine the use case,” than to imply that advisor is actively opening commercial doors if they are not.

Precision builds trust because it survives reference calls.

The strongest founders do not need to inflate. They understand that investors will check. They know that a clean, honest description of progress is more valuable than an impressive claim that becomes weaker once the market is contacted.

Share

References reveal how the company behaves

Formal diligence often tests what the company has done. Informal references often reveal how the company behaves.

This matters because early-stage companies are not fully formed. Investors are not only evaluating assets, but patterns. They want to understand how the founder handles pressure, feedback, complexity, and relationships. They want to know whether the company learns quickly, communicates clearly, follows through, and earns trust over time.

A customer reference may reveal whether the company understands workflow reality. An advisor reference may reveal whether the founder can filter advice. A former colleague may reveal whether the founder is resilient, difficult, disciplined, chaotic, or unusually effective. A co-investor may reveal whether the founder communicates well when things are not going perfectly. An operator may reveal whether the product is credible or fragile. A sector expert may reveal whether the market need is urgent or only academically interesting.

These signals are powerful because they come from outside the founder’s controlled narrative.

Investors know every founder is selling during fundraising. That is expected. The purpose of references is to understand what remains true when the founder is not pitching. Does the company still sound compelling when described by someone else? Does the founder’s reputation support the level of trust required? Do customers describe real pain? Do people who know the space agree that the wedge makes sense? Do people around the company believe the founder can execute?

The market does not need to be universally positive. No company is liked by everyone. But the pattern matters. One cautious comment may not mean much. Repeated concerns across several calls are different.

Investors listen for patterns.

The references you do not choose may matter most

Founders usually prepare formal references carefully. They select the customer who loves the product, the advisor who is supportive, the investor who believes in the company, and the operator who understands the market. Those references can help, but investors know they are selected.

The more revealing references are often the ones the founder does not choose.

Investors may speak to a customer who did not convert. They may speak to someone who used to advise the company. They may speak to a former employee. They may speak to an investor who passed. They may speak to a buyer in the same category who has not heard of the company. They may speak to a competitor’s customer. They may speak to someone who understands the workflow, reimbursement, regulatory, or procurement challenge better than the founder expects.

These conversations can be valuable because they provide texture. They help investors understand whether the company’s challenge is normal, serious, hidden, or misunderstood. A lost customer may still validate the pain. A passed investor may still respect the founder. A cautious operator may still confirm the market is moving. A former advisor may still say the founder is excellent, but early.

The danger is not that every reference must be perfect. The danger is when the founder has not thought about what unselected references might say.

If the founder knows why a customer did not convert, they can explain it. If they know why an investor passed, they can interpret the signal. If they know why a pilot stalled, they can show what was learned. If they know where the market is sceptical, they can address it directly.

Founders lose control when they are surprised by the market’s own version of the company.

Leave a comment

The market can validate what the deck cannot

Reference calls are not only a risk. They can also be one of the strongest assets in a fundraising process.

A deck can explain that the problem is urgent. A customer can confirm that it is urgent. A data room can show early usage. A buyer can explain why the workflow matters. A founder can describe the market gap. A sector expert can confirm that the gap is real. A company can claim that implementation is manageable. An operator can explain why the team has made the right tradeoffs.

This is powerful because investors trust independent confirmation. They know the founder has an incentive to make the company sound attractive. When people around the market confirm the same story, the investor’s confidence increases.

The strongest fundraising processes often have this kind of external reinforcement. The investor hears the founder’s story, then hears similar language from customers, advisors, operators, or sector experts. The same themes repeat. The pain is real. The founder is credible. The product is relevant. The team listens. The use case is clear. The market is early but moving. The risk is understood. The next milestone makes sense.

That consistency creates conviction.

This is why founders should think of references as part of company building, not only fundraising. Every customer conversation, advisor interaction, pilot, investor update, and partnership discussion is shaping what the market might say later. A founder who communicates clearly and behaves consistently creates a stronger informal diligence trail.

The company’s reputation is built before the investor starts checking it.

Health makes reference calls more important

In health, informal diligence matters because the market is complex. Investors often need help understanding whether a claim is credible. A generalist investor may need to speak to clinicians, health system leaders, reimbursement experts, regulatory advisors, pharma operators, or specialist investors. Even specialist investors use references to pressure test the practical reality behind the story.

A product may look compelling in a deck, but a clinician can explain whether it fits the workflow. A market may look large, but a buyer can explain whether there is budget. A diagnostic may show promising performance, but an expert can explain whether the evidence package is sufficient. A digital health product may claim ROI, but an operator can explain whether implementation would slow adoption. A therapeutic platform may look exciting, but a specialist can explain whether the translational logic is strong enough.

This is not a weakness of health investing. It is the nature of the sector.

Health companies sit inside systems that are regulated, budget-constrained, evidence-driven, politically complex, and slow to change. No investor can understand every piece from the deck alone. Reference calls help investors understand the reality around the company.

This is also why founder credibility matters so much. Investors know that health founders must navigate stakeholders who do not all think the same way. Clinicians, buyers, regulators, payers, pharma teams, patients, investors, and strategic partners may each see a different risk. A founder who earns trust across those groups becomes more backable. A founder who creates confusion across those groups becomes harder to underwrite.

In health, the market does not only validate the product. It validates the founder’s ability to navigate the system.

Your narrative has to travel without you

One of the most important tests in fundraising is whether the company’s story can travel without the founder in the room. Reference calls are one way investors test this.

When an investor speaks to someone around the market, they are not only asking, “Is this company good?” They are also asking, “Does the company mean the same thing to others as it means to the founder?”

If the founder says the company solves an urgent workflow problem, do customers describe the same urgency? If the founder says the product reduces burden, do users describe that value clearly? If the founder says a partnership is strategic, does the partner see it that way? If the founder says the next milestone matters, do experts agree that it changes the risk profile?

When the story travels cleanly, the investor gains confidence. When the story changes too much depending on who is speaking, the investor may worry that the company is not yet clear enough.

This is why founders need to make the company easy for others to describe. Customers should be able to explain the value. Advisors should be able to explain where the company fits. Existing investors should be able to explain the next milestone. Team members should be able to explain the wedge. Strategic partners should be able to explain why the company matters to them.

The founder does not need everyone to use the same words. But the meaning should be consistent.

A company becomes more investable when the market can repeat its logic.

Share

How to prepare for informal diligence

The deeper question is not how to control every reference call. You cannot. The better question is how to build a company whose market story can survive diligence.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most frustrating moments in fundraising is when the founder has a lot of investor interest, but no lead investor.

The meetings are happening. The feedback is positive. Investors like the market. They like the team. They like the problem. They ask for updates. They say they want to stay close. They ask who else is in the round. They say they could follow. They say the company is interesting. They may even say they would like to participate once the round comes together.

From the outside, this can look like momentum.

From the inside, it can feel like the round is almost working.

But the round is not really working until someone is willing to lead.

This is the lead investor problem. It happens when many investors are interested in the company, but no one is willing to take ownership of the round. Everyone wants to watch. Everyone wants to be kept updated. Everyone wants to know who else is involved. Everyone wants comfort from the market. But nobody wants to set the terms, anchor the round, take the first real risk, and become the investor others can organise around.

Founders often misunderstand this stage. They think the problem is lack of exposure. So they take more meetings. They send more updates. They widen the process. They speak to more funds, angels, family offices, strategics, and advisors. They assume that if enough people are interested, the round will eventually come together.

Sometimes that is true. But often, more interest does not solve the problem.

Because interest is not leadership.

A lead investor does more than write a cheque. A lead investor gives the round structure. They set or negotiate the terms. They define the valuation conversation. They validate the opportunity for other investors. They help create urgency. They become a signal that someone has done the work, taken the risk, and decided the company is worth backing now.

Without a lead, the round can drift. Investors wait for each other. Nobody wants to be first. Nobody wants to price the risk. Nobody wants to take responsibility for the terms. The founder keeps hearing positive language, but the company does not move closer to a signed term sheet.

This is one of the reasons fundraising can feel so confusing. A founder can have a full pipeline and still not have a round.

Subscribe now

Interest is easy. Leadership is hard.

Investor interest is not meaningless. It can be useful. It tells the founder that the company is worth discussing. It can create market feedback. It can help refine the story. It may turn into future participation. It can also be helpful once a lead is in place.

But interest is a low-commitment position.

An investor can be interested without being ready to invest. They can like the company without believing the price. They can like the founder without understanding the market deeply enough. They can like the sector but not have conviction on this specific opportunity. They can believe the company may become fundable later, but not want to take the risk now.

A lead investor has to cross a much higher threshold. They need enough conviction to move from observation to ownership. They need to believe the company is worth spending real time on. They need to defend the investment internally. They need to underwrite the risk. They need to decide what terms make sense. They need to be comfortable being the investor others look to for confidence.

That is a very different decision.

This is why founders should be careful with investor language. “We are interested” does not mean “we will lead.” “Keep us updated” does not mean “we are close.” “We could participate” does not mean “we are willing to anchor.” “We like the company” does not mean “we will take pricing risk.”

Investors are often polite because they do not want to close doors too early. They may genuinely like the opportunity but still not be ready to lead. The founder’s job is to understand where the investor sits on the spectrum between curiosity and conviction.

The fundraising process becomes much clearer when the founder stops treating all positive investor feedback as equal.

Followers behave differently from leads

Not every investor wants to lead. Some funds are designed to lead rounds. Others are designed to follow. Some angels can move quickly but cannot price or structure the round. Some family offices may be flexible, but still want an institutional lead. Some strategics may be interested, but not suitable to lead a priced venture round. Some funds may only participate once another investor has set terms.

This is not necessarily bad. Followers can be valuable. They can fill out a round, bring expertise, add networks, support later financing, or strengthen the syndicate. But followers rarely solve the hardest part of the raise.

The hardest part is getting the first investor to take responsibility.

Followers often ask the same question: who is leading? That question is not just administrative. It tells you how they think about risk. They may not want to do full diligence independently. They may not want to negotiate terms. They may not want to be the first institutional signal. They may not want to take reputational risk if the round does not come together.

Once there is a credible lead, many followers become more comfortable. The round has a price. The diligence has an anchor. The founder has validation. The process has urgency. The decision becomes easier.

This is why a founder can spend months collecting soft commitments and still feel stuck. A round full of conditional followers is not the same as a round with a lead.

The founder needs to know which investors in the process are capable of leading, which are willing to lead, and which are only likely to follow. Those are different categories. A fund may have the capital to lead but not the conviction. Another investor may have the conviction but not the cheque size. Another may like the company but not have the mandate. Another may want to wait until the next round.

If the founder does not separate these categories, the pipeline becomes misleading.

The lead investor creates the market for the round

A financing round is not just a collection of individual investor decisions. It is also a market. Investors are watching each other. They are interpreting who is involved, who is moving, who is delaying, who has conviction, who passed, who is leading, and who is following.

The lead investor helps create that market.

When a credible lead commits, the round becomes easier for others to understand. There is a term sheet. There is a valuation. There is a structure. There is a diligence reference point. There is a signal that someone with capital and judgment has decided the opportunity is worth anchoring.

This does not remove the need for other investors to do their own work. Good investors still make independent decisions. But the existence of a lead changes the psychology of the round. It reduces uncertainty. It creates a point around which other investors can organise.

Without a lead, the founder has to create all of that alone. They have to convince each investor individually, while also trying to prove that other investors are moving. This can become circular. Investors wait for a lead because there is no lead. No lead appears because everyone is waiting.

Founders often try to solve this with pressure. They say the round is moving. They imply there is strong demand. They mention investor names carefully. They try to create urgency. That can work if there is real movement behind it. But if the process is mostly soft interest, investors can feel the difference.

The strongest urgency comes from real conviction, not manufactured momentum.

A lead investor gives the round gravity.

Why investors avoid leading

It is useful to understand why investors avoid leading, even when they like the company.

Leading takes work. The lead has to do deeper diligence, negotiate terms, manage internal conviction, think about ownership, evaluate future financing risk, and often help organise the syndicate. It is much easier to follow someone else’s work than to lead from the front.

Leading also creates reputational risk. If a fund leads a round, other investors assume they have done serious diligence. If the company later struggles, the lead’s judgment is visible. This does not mean investors are afraid of risk. Venture capital requires risk. But investors are selective about which risks they want to own.

There is also pricing risk. Setting the valuation is difficult, especially in early health companies where evidence, market access, regulation, clinical development, reimbursement, and commercial adoption may still be uncertain. A follower can accept terms once they exist. A lead has to decide what those terms should be.

For funds, leading also affects portfolio construction. A lead investor usually needs meaningful ownership. That may require a larger cheque than the founder expects. The fund has to think about reserves, future follow-on needs, concentration, and whether the company fits its mandate. Even if the partner likes the company, the round may not work for the fund.

This is why founders should not assume that a lack of lead interest means the company is bad. Sometimes the issue is fund fit. Sometimes it is timing. Sometimes it is ownership. Sometimes it is stage. Sometimes it is the future capital requirement. Sometimes the company is interesting, but not yet leadable.

The key question is not only whether investors like the company.

The question is whether the company is ready for someone to own the risk.

Lead investors need a stronger case than followers

A founder can often persuade a follower with a good story, a credible lead, and a reasonable allocation. The follower may do diligence, but the decision is partly supported by the structure already created by the lead.

A lead needs more.

A lead needs to understand the company deeply enough to take responsibility for the investment case. They need to know why now, why this team, why this market, why this wedge, why this round, why this valuation, and why this risk is worth taking. They need to know what the company will prove with the capital and why that proof point matters for the next financing or strategic outcome.

This is where many founders struggle. They are able to create interest, but not enough conviction for leadership.

The company may be exciting, but the round logic is unclear. The market may be large, but the first buyer is not clear enough. The science may be strong, but the commercial path is still too broad. The team may be impressive, but the next milestone does not change the financing case. The founder may have many conversations, but no sharp answer to why this round should be led now.

A lead investor does not want to feel like they are financing activity. They want to feel like they are financing a specific value creation step.

This is especially important in health because the path can be long and capital-intensive. The lead has to believe that this round is not just keeping the company alive. It is moving the company to a stronger position. That could mean stronger evidence, clearer adoption, regulatory progress, commercial proof, strategic partnership readiness, or a financing milestone that makes the next round more credible.

If the round does not create a meaningful change in the company’s risk profile, it becomes harder to lead.

The “we have interest” trap

Founders often say, “We have a lot of investor interest.” That may be true, but it is not enough.

The important question is what kind of interest.

Is the investor willing to lead? Are they doing real diligence? Have they discussed cheque size? Have they talked about ownership? Have they introduced terms? Have they taken it to partnership? Have they asked for references? Have they given a process timeline? Have they explained what they need to believe in order to move forward?

Or are they simply staying close?

The difference matters. A founder can easily mistake polite investor engagement for real round momentum. This creates the “we have interest” trap. The founder keeps spending time with investors who are not likely to lead, while the round loses energy. The process feels active, but the central problem remains unsolved.

This can become dangerous because fundraising windows are emotional and strategic. If the founder waits too long to realise there is no lead, they may run out of time, lose leverage, or be forced to accept weaker terms. They may also burn investor attention by sending repeated updates without creating a real decision point.

The founder needs to qualify interest early.

A simple question can change the process: “Is this a round you would consider leading, or would you be more likely to participate alongside a lead?”

That question may feel uncomfortable, but it saves time. It allows the founder to understand the investor’s role. It also shows maturity. Good founders do not just collect conversations. They manage the financing process.

Not every round needs the same kind of lead

The lead investor problem looks different depending on the round.

At pre-seed, the lead might be an angel, operator, micro fund, family office, or specialist seed investor willing to anchor the first institutional cheque. At seed, the lead may need to set terms, help build the syndicate, and provide enough credibility for other investors to follow. At Series A, the lead usually needs deeper conviction, stronger ownership, and the ability to support future rounds. In life sciences and health, the lead may also need to understand regulatory, clinical, commercial, and capital intensity risk.

The founder needs to know what kind of lead the round requires.

Some founders are looking for a lead investor, but they are speaking mostly to followers. Others are speaking to funds that lead, but only at a later stage. Some are speaking to investors with sector interest, but not enough cheque size. Some are speaking to strategics who may be helpful, but cannot provide the venture signal the round needs. Some are speaking to family offices that can write capital, but do not want to set terms.

This creates confusion because the founder may think they are running a fundraising process, when they are actually running a broad investor awareness process.

A fundraising process needs a clear target. Who can lead this round? What cheque size is required? What ownership range makes sense? What stage does the investor lead? What kind of companies do they lead? What evidence do they need? What is their decision process? What is their fund timing?

Without this clarity, the founder may spend months in meetings that were never likely to produce a lead.

The lead investor is underwriting the next round too

A lead investor is not only thinking about this round. They are thinking about what happens after this round.

Can the company reach a milestone that attracts the next investor? Will the next round be financeable? Will the syndicate be strong enough? Will the company need too much capital before major proof? Will the market be ready? Will the valuation leave room for the next financing? Will there be enough future investor appetite?

This downstream financing risk matters. A lead does not want to anchor a round that leaves the company stranded. They want to believe that the company can become more fundable after the capital is deployed. If the next financing looks difficult, the current round becomes harder to lead.

This is one reason founders need to explain the round in terms of value creation, not just runway. “This round gives us 18 months” is not enough. The investor wants to know what the company will look like after those 18 months. What will be proven? What will be de-risked? What will be more valuable? What new investors will care? What strategic options will open?

The lead investor is thinking like the first buyer of the financing risk. If they lead now, they need to believe there will be a market for the company later.

That is why the round story matters so much.

Share

A weak syndicate can make leading harder

Lead investors also care about the rest of the syndicate. They want to know who else is coming in, who already owns the company, whether existing investors are supportive, and whether the cap table will help or hurt future financing.

A weak syndicate can make a round harder to lead. If existing investors are not participating, that creates questions. If the cap table is crowded with passive angels, that may create governance or signalling concerns. If strategic investors have rights that could complicate future financing or exit paths, that may create hesitation. If the founder is trying to fill the round with investors who bring no follow-on capacity, the lead may worry about future support.

This does not mean every company needs a perfect cap table. Early companies rarely do. But the lead investor wants to understand what they are joining.

They are not just investing in the company. They are joining the ownership structure around the company.

Founders sometimes underestimate how much this matters. They think capital is capital. Investors know that capital has behaviour. Some investors support. Some disappear. Some complicate decisions. Some create signalling risk. Some help recruit, finance, partner, and build. Some make the next round easier. Others make it harder.

A strong lead does not only care about getting into the round. They care about whether the round creates a company that can be financed again.

How to make a round leadable

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Many founders think the company becomes more impressive when it is doing more.

More markets. More customer types. More use cases. More partnerships. More pilots. More investor narratives. More strategic options. More product directions. More possible business models. More ways the company could win.

From the inside, this can feel like ambition. The founder sees the scale of the opportunity and wants investors to understand how much the company could become. They want to show the platform potential, the market breadth, the customer demand, the strategic relevance, and the number of doors that appear to be opening.

But from the outside, doing more can create a different signal.

It can make the company look less clear.

This is one of the most common problems in early-stage fundraising. The founder is working hard, the company is active, the story is full of potential, and there are many possible paths forward. But the investor struggles to understand what the company is actually choosing.

That matters because investors do not just fund activity. They fund focus. They need to believe that the founder understands which path creates the most value, which risk matters first, which customer matters now, which market should be prioritised, and which milestone the round is designed to unlock.

The strategic clarity problem appears when a company has motion but not enough direction. The founder can describe many opportunities, but not the sequence. They can explain many use cases, but not the wedge. They can talk about many customer types, but not the buyer. They can reference many partnerships, but not the commercial logic. They can show many investor narratives, but not one strong investment case.

This does not mean ambition is bad. Investors want founders who see large outcomes. They want companies with room to grow. They want businesses that can become much bigger than the first product, first customer, or first market. But ambition needs structure. Without structure, breadth starts to look like confusion.

The strongest founders do not make the company look bigger by saying yes to everything. They make the company look more investable by showing what matters first.

Subscribe now

Activity is not strategy

Early companies are full of activity. That is normal. Founders need to speak to customers, build product, test assumptions, recruit talent, raise capital, manage advisors, explore partnerships, and create momentum before the company has institutional support around it.

The problem begins when activity starts to replace strategy.

A founder may have twenty customer conversations, but no clear view of which customer segment matters most. They may have several pilot discussions, but no defined criteria for which one should move forward. They may speak to investors across different categories, but keep changing the story depending on who is listening. They may pursue partnerships because the logos look impressive, without knowing whether those partnerships reduce a real risk.

This can create the appearance of progress while hiding a lack of prioritisation. The company is busy, but the direction is still unclear. Investors can sense this quickly because fundraising forces the founder to explain not only what is happening, but why it matters.

When an investor asks what the next twelve months are meant to prove, the answer cannot be a list of activities. It needs to be a strategic argument. The company is choosing this market because it creates the cleanest path to evidence. It is prioritising this customer because they have the clearest pain, budget, and adoption pathway. It is building this product wedge because it reduces the most important risk. It is raising this amount because it gets the company to a milestone that changes the financing case.

That is strategy.

Strategy is not everything the company could do. It is the discipline to choose what the company should do now.

Too many markets create investor doubt

One of the fastest ways to lose investor confidence is to present too many markets at once. This happens often in health because many technologies genuinely have broad potential. A diagnostic platform may apply across several disease areas. A digital health product may help providers, payers, employers, and pharma. A medtech innovation may have multiple clinical use cases. A data platform may be relevant to hospitals, life sciences companies, insurers, and public health systems.

The founder sees this breadth as strength. The investor often sees it as unfinished thinking.

The issue is not whether the company could eventually serve multiple markets. The issue is whether the founder knows which market creates the strongest first investment case. Investors are not only asking where the company could go. They are asking where the company should start, why that starting point is credible, and what it proves about the larger opportunity.

If every market is presented as equally attractive, the investor has to do the prioritisation themselves. That creates friction. It also raises concerns that the founder may not understand the adoption path deeply enough. Different markets have different buyers, budgets, timelines, evidence needs, regulatory questions, pricing models, and sales motions. A company that tries to pursue all of them too early can spread itself thin and learn too slowly.

Focus does not make the company smaller. It makes the first path more believable.

A founder can still explain the broader vision, but the first market needs to be clear. The investor should understand why this market comes first, what evidence supports that choice, what will be learned, and how success there opens the next path. Without that sequence, the market story becomes a collection of possibilities rather than a strategy.

Too many customer types weaken the buyer story

The same problem appears with customer types. Many founders describe several possible buyers because they do not want to close off optionality. They say the product could be sold to hospitals, clinics, pharma companies, payers, employers, consumers, governments, or research institutions. In some cases, that may be true. But it also creates a serious problem.

Each customer type represents a different business.

A hospital buyer is not the same as a pharma buyer. A payer is not the same as an employer. A clinician is not the same as a procurement department. A patient user is not the same as an institutional customer. A research team is not the same as a commercial buyer. Each has a different problem, incentive, budget, decision process, implementation barrier, evidence requirement, and sales cycle.

When a founder describes too many customers at once, investors may worry that the company has not yet found its buyer. That is different from having a large market. A large market is useful only if the company knows how to enter it. Without a clear buyer, the go-to-market strategy becomes vague.

This matters because investors need to understand how demand becomes revenue. Interest is not enough. Clinical enthusiasm is not enough. Strategic curiosity is not enough. The buyer story has to explain who feels the pain strongly enough to act, who controls the budget, who influences the decision, what evidence they need, how long the process takes, and what makes the purchase urgent.

A founder who cannot answer this clearly may still have a strong product, but the commercial path will feel weak. The investor may like the opportunity and still pass because the company has not made a clear strategic choice about who it is serving first.

Too many use cases make the product harder to believe

Use case expansion is another common source of strategic confusion. Founders often want to show that the product can solve many problems. The platform can support many workflows. The technology can apply to many disease areas. The data can inform many decisions. The tool can serve several parts of the organisation.

Again, the founder sees this as upside. Investors may see it as a lack of discipline.

Every use case adds complexity. It may require a different workflow, different evidence, different user behaviour, different integration, different success metric, and different buyer conversation. Even when the underlying technology is the same, the adoption path may not be.

If the founder leads with too many use cases, the investor may struggle to understand what the company is actually building. Is this a product, a platform, a service, an infrastructure layer, a clinical tool, a workflow solution, a data asset, or a strategic capability? More importantly, which use case proves the company is valuable?

The strongest founders are able to separate future optionality from current focus. They can say, “This could apply more broadly, but this is the use case we are prioritising because it has the clearest pain, the strongest evidence path, the most urgent buyer, and the best route to adoption.”

That sentence creates confidence because it shows judgment. It tells the investor the founder is not trying to win every possible market at once. They are choosing the use case that can make the company easier to believe.

A narrow wedge is not a lack of ambition. It is often the only way to make ambition fundable.

Share

Partnerships can become strategic noise

Partnerships are often used to show momentum. Founders mention conversations with hospitals, pharma companies, universities, corporates, distributors, accelerators, innovation teams, strategic investors, and international partners. These relationships may be useful, but they can also create noise if the founder cannot explain their purpose.

Investors do not automatically value partnership activity. They want to know what each partnership changes.

Does it give access to customers? Does it reduce clinical risk? Does it support regulatory progress? Does it create distribution leverage? Does it generate revenue? Does it validate demand? Does it help with data access? Does it shorten the path to market? Does it make the company more valuable before the next round?

If the founder cannot answer those questions, the partnership may look like activity rather than strategy.

This is especially important in health because the sector is full of slow-moving partnership conversations. A company can spend months speaking to respected institutions without getting closer to revenue, adoption, evidence, or investment readiness. The logos may look impressive, but investors have seen enough exploratory conversations to know that not all strategic interest converts into company value.

A clear founder knows which partnerships matter and why. They do not collect logos for the deck. They use partnerships to reduce specific risks, open specific markets, or create specific proof points. That distinction is important.

Partnerships should sharpen the investment case, not make it harder to understand.

Too many investor narratives create confusion

Founders often adjust the story depending on the investor. A healthtech founder may present as a digital health company to one fund, an AI company to another, a data infrastructure company to another, a clinical workflow company to another, and a pharma services company to another. Some flexibility is useful. Different investors care about different parts of the story.

But too much narrative flexibility becomes dangerous.

If the founder changes the company too much depending on the room, investors may wonder whether there is a clear strategy underneath the pitch. A company can have multiple angles, but it should not feel like a different business each time. The narrative should adapt to the audience without losing the core investment logic.

This matters because investors need to carry the story internally. If the founder cannot explain the company with strategic clarity, the investor cannot easily explain it to partners, investment committees, advisors, or co-investors. The story becomes harder to defend. The company becomes harder to categorise. The decision becomes harder to make.

The founder’s job is not to say whatever sounds most attractive to each investor. It is to explain the company clearly enough that the right investors understand why it fits their mandate.

Not every investor needs to like the company. But the right investor needs to understand it.

Strategic clarity helps the founder stop chasing every possible interpretation of the business and start building conviction around the one that matters most.

Focus is not the opposite of ambition

Many founders resist focus because they worry it will make the company look smaller. They want to show a large market, a platform opportunity, multiple revenue streams, international potential, and strategic optionality. They worry that choosing one path will reduce investor excitement.

This is a misunderstanding of how investors think.

Focus does not make ambition smaller. Focus makes ambition believable.

Investors can understand that a company may expand over time. They can underwrite a wedge that opens into a larger market. They can believe in a platform if the first application proves something important. They can back a company with multiple future paths if the first path is strong enough to carry the financing case.

What they struggle with is a company that wants credit for every future possibility before proving one current path.

Strategic clarity is the bridge between ambition and belief. It tells the investor how the company moves from now to later. It explains which proof point comes first, why it matters, and how it changes the next decision. It gives the investor a way to understand risk, sequencing, capital use, and value creation.

The best founders can hold both ideas at once. They can explain the big vision and the immediate focus. They can show the long-term opportunity without pretending everything must happen now. They can make the company feel large without making it feel scattered.

That is the difference between ambition and strategic confusion.

Leave a comment

Strategic clarity is a leadership signal

Investors read strategic clarity as a leadership signal. It tells them how the founder thinks, not just what the company does. A founder who can prioritise clearly is more likely to use capital well. A founder who can say no is more likely to avoid distraction. A founder who can sequence risk is more likely to survive a difficult market. A founder who can explain tradeoffs is more likely to lead a team through uncertainty.

This is why strategic clarity matters before the company is fully mature. Investors know early companies will change. They are not expecting the founder to have every answer. But they do expect the founder to know what matters now.

A founder who says, “We are exploring several markets,” may sound open-minded. A founder who says, “We explored several markets, and we are prioritising this one because it gives us the strongest path to adoption and evidence,” sounds much stronger.

A founder who says, “There are many use cases,” may sound ambitious. A founder who says, “There are many possible use cases, but this one is the wedge because it creates the clearest buyer urgency,” sounds more investable.

A founder who says, “We have lots of partnership conversations,” may sound active. A founder who says, “These two partnerships matter because they reduce implementation risk and create access to the customer segment we are prioritising,” sounds strategic.

The difference is not effort. It is judgment.

The choices investors want to see

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Every early-stage company depends on the founder. That is normal. In the beginning, the founder carries the story, sells the vision, recruits the first team, speaks to customers, manages advisors, raises capital, builds the first partnerships, shapes the product, and keeps the company moving when there is not yet enough structure around it.

Founder force is often the reason the company exists at all.

But there is a point where founder force becomes founder bottleneck.

This is one of the most important transitions in company building. At the earliest stage, investors expect the company to move through the founder. They know the founder will be personally involved in every customer conversation, investor meeting, product decision, hiring discussion, and strategic choice. But as the company develops, investors start asking a different question. Can this company begin to operate beyond the founder’s personal intensity?

That is where many early health companies get stuck. The founder is still the only person who can sell the product, explain the science, manage the pilot, speak to investors, handle partnerships, make product decisions, recruit talent, update the data room, and interpret the market. Every important decision routes through one person. Every relationship depends on one person. Every piece of momentum requires the founder to push it personally.

From the inside, this can feel like leadership.

From the outside, it can start to look like fragility.

This is the founder bottleneck. It happens when the company has no real operating system beyond the founder’s effort. The founder is busy, committed, and often impressive, but the business itself has not yet learned how to move without them touching everything.

Investors worry about this because venture capital is not only funding what the founder can do personally. It is funding whether the company can become larger, stronger, more repeatable, and more valuable over time. A company that only moves through founder force may be exciting, but it can also be difficult to scale.

Subscribe now

Founder force gets you started

There is nothing wrong with founder force at the beginning. In fact, most companies need it. Early-stage companies do not have brand, process, reputation, systems, or institutional momentum. They have the founder’s conviction and the founder’s ability to create movement before the market gives movement back.

This is especially true in health. The first customer conversations are often founder-led because the founder can explain the nuance of the problem. The first investor meetings are founder-led because the founder can connect the story, the evidence, and the ambition. The first partnerships are often founder-led because trust is personal at the beginning. The first hires usually join because they believe in the founder’s clarity and energy.

That is expected. Investors know early companies are not mature organisations. They know the founder has to do uncomfortable things before the company has process around them. The founder may have to sell before there is a sales team, manage product before there is a product leader, discuss regulation before there is a regulatory hire, and handle fundraising while still running the company day to day.

But founder force is supposed to create the conditions for the company to become less dependent on founder force.

The danger is when the founder remains the only source of movement. If every pilot needs the founder, every customer needs the founder, every investor update needs the founder, every product tradeoff needs the founder, and every internal decision waits for the founder, the company is not becoming stronger. It is becoming more dependent.

That dependence may not look dangerous at first. The founder is often capable enough to keep things moving. But as the company grows, the number of decisions increases, the number of stakeholders increases, and the cost of founder dependency becomes harder to hide.

Investors look for repeatability

One of the things investors are trying to understand is whether early progress can repeat. A founder may be able to sell the first pilot because they are persuasive, credible, and deeply connected to the mission. But can someone else sell the second, third, and fourth? A founder may be able to hold the product together because they understand every customer conversation, but can the team make product decisions without waiting for the founder’s interpretation? A founder may be able to explain the company beautifully to investors, but can the materials, data room, and team carry the story when the founder is not in the room?

This is why founder dependency becomes an investor concern. The investor is not trying to take the founder out of the company. They are trying to understand whether the company has begun to convert founder knowledge into company capability.

There is a difference between a founder who is essential and a founder who is blocking scale. The founder should remain essential to the company’s direction, culture, judgment, and mission. But the company should not require the founder to manually push every function forward.

Investors want to see signs that the company is becoming repeatable. They want to know whether customer learning is being captured, whether sales conversations follow a pattern, whether product decisions are connected to evidence, whether hiring is filling real gaps, whether the team understands priorities, and whether the company can execute without everything becoming a founder decision.

This does not mean the company needs heavy process. Early-stage companies should not become bureaucratic. But they do need operating discipline. They need enough structure for learning, decisions, execution, and communication to compound beyond one person.

Without that, the company may look busy but not scalable.

The founder becomes the keeper of context

One of the most common signs of a founder bottleneck is that the founder becomes the keeper of all context. They remember what customers said. They remember why investors passed. They remember which advisor warned about regulatory risk. They remember why the product roadmap changed. They remember why one market was deprioritised, and another was chosen. They remember the history behind every decision.

At the beginning, this is natural. The founder is closest to the market and usually has the most complete understanding of the company. But over time, this becomes a problem if the context never leaves the founder’s head.

The team cannot make strong decisions because the reasoning behind previous decisions is not visible. New hires take longer to become effective because they are missing the market history. Advisors repeat old suggestions because they do not know what has already been tested. Investors ask for evidence, but the founder has to reconstruct the story from memory. Product discussions drift because the team does not have a shared view of what the market is teaching the company.

This creates hidden drag. Nothing appears broken immediately, but everything becomes slower. The founder has to explain more, approve more, correct more, remember more, and intervene more. The company becomes dependent on the founder not only for decisions, but for interpretation.

That is not scalable.

A company becomes stronger when founder context becomes company knowledge. Customer learning should inform the team. Investor objections should improve the fundraising story. Pilot lessons should shape product and implementation. Advisor input should be captured and filtered. Strategic choices should be documented enough that others understand why they were made.

This is how the company starts to operate beyond the founder’s memory.

Founder-led sales can hide weak sales maturity

Founder-led sales are normal at the beginning. In many health companies, they are necessary. The founder understands the problem deeply, can adapt the conversation in real time, and can build trust with early customers. In complex markets, early sales often require founder credibility.

But founder-led sales can also hide weak commercial maturity.

A founder may be able to get meetings because they are compelling, connected, or mission-driven. They may be able to create interest because they can explain the problem with intensity. They may be able to keep pilots alive because they personally follow up, solve issues, and maintain relationships. But investors will eventually ask whether this motion can scale.

If the founder is the only person who can sell, the company has not yet proven a sales motion. It has proven founder persuasion. That may be valuable, but it is not the same thing.

Investors will want to know whether the company understands the buyer, the budget, the objection patterns, the sales cycle, the implementation steps, and the conversion path. They will want to see whether the founder has turned early conversations into a repeatable process. They will want to know whether someone else could eventually follow the same logic and produce similar results.

This is especially important in health because early relationships can be highly personal. A clinician may support the company because they like the founder. A hospital may explore a pilot because the founder has built trust. A strategic partner may keep the conversation open because the founder is persistent. These are useful signals, but they are not enough unless the company can show that the relationship is becoming a repeatable commercial pattern.

The best founders use founder-led sales to learn the market, not to remain permanently at the centre of every sale.

Product decisions cannot all depend on the founder

The founder bottleneck also appears in product. Early product direction often depends heavily on the founder because the founder understands the original insight. They know the customer pain, the market gap, the scientific logic, the clinical workflow, or the technical opportunity that gave birth to the company.

But as the company grows, product decisions need to become more disciplined. If every feature, roadmap change, workflow adjustment, and implementation decision depends on the founder, the team cannot move quickly or confidently. The founder becomes the filter for everything.

This is dangerous because the founder may not always be the best product decision-maker at every stage. They may be too close to the original idea. They may overvalue certain customer conversations. They may resist narrowing the product because they see the full vision. They may add features because they want to keep every stakeholder happy. They may delay difficult tradeoffs because they personally feel the cost of saying no.

A good product process does not remove the founder’s judgment. It gives that judgment leverage. The team should understand the first wedge, the customer evidence, the adoption barriers, the success criteria, and the next milestone well enough to make decisions without waiting for the founder every time.

This matters to investors because product maturity is not only about what has been built. It is about how product decisions are made. A company that can explain why it is building one thing and not another shows focus. A company that keeps routing product through founder instinct alone may look less mature, even if the product itself is impressive.

Hiring should reduce founder dependency

Hiring is one of the clearest tests of whether a founder is building a company or simply adding people around themselves. Early hiring should reduce founder dependency. The right hire should take ownership of a real function, increase the quality of decisions, and create more leverage for the company. But many founders hire without actually letting go.

This happens for understandable reasons. The founder knows the company best. They have high standards. They worry that others will not explain the company correctly, manage customers properly, make the right product tradeoffs, or handle investors with enough care. So they hire people, but keep the real decision-making centralised.

The team grows, but the bottleneck remains.

Investors notice this. They look at the team and ask whether the company has real functional ownership or only support around the founder. Who owns product? Who owns commercial execution? Who owns clinical development? Who owns operations? Who owns finance? Who owns regulatory thinking? Who owns investor materials? Who is accountable for what?

At the early stage, not every role will be fully filled. That is fine. But the founder should understand which capabilities need to move out of their head and into the company. A founder who cannot delegate real ownership may struggle to scale, even with more capital.

This is why hiring is not just about adding talent. It is about changing how the company works.

Share

The board and advisors should not become another founder task

Advisors and boards can help reduce founder bottlenecks, but only if used properly. In many early companies, the founder manages advisors reactively. They reach out when there is a problem, ask for feedback, absorb conflicting opinions, and then try to decide what to do. The advisory structure becomes another thing the founder has to carry.

The same can happen with boards. Instead of using the board to sharpen decisions, the founder uses board meetings to report activity. The board hears updates, but the founder still carries all the decisions back into the company. The governance structure exists, but it does not create enough leverage.

This is a missed opportunity. Good advisors and board members should help the company see around corners, make better choices, pressure test assumptions, and reduce founder isolation. But they need context, structure, and clear asks. Otherwise, they become noise.

A founder who uses advisors well can reduce their own bottleneck. They can bring the right question to the right person at the right time. They can distinguish between advice that changes strategy and advice that should be noted but not acted on. They can use the board to clarify decisions, not just review progress.

This matters because investors want to know whether the founder can build around themselves. A founder who tries to solve every problem personally may be impressive, but they also create concentration risk. A founder who knows how to use people, process, and governance intelligently creates more confidence.

The company needs rhythm

One of the best ways to move beyond founder force is to build rhythm. Rhythm does not mean bureaucracy. It means the company has a consistent way of learning, deciding, executing, and communicating.

A company with rhythm captures customer learning. It reviews what the market is saying. It knows which risks matter this month. It connects product decisions to evidence. It understands what the next milestone requires. It communicates progress clearly to investors and advisors. It has a cadence for making decisions instead of letting every issue become a founder emergency.

This kind of rhythm creates trust because it shows the company is becoming more than a collection of founder reactions. It has a way of operating. Even if the team is small, the company starts to feel more mature.

In health, rhythm matters because progress is often slow. Without rhythm, slow progress can turn into anxiety. The founder starts chasing every signal, reacting to every delay, and pushing activity just to feel movement. With rhythm, the company can stay focused even when the market is moving slowly. It can keep learning, keep building evidence, and keep making disciplined decisions.

Investors are not expecting perfection. They are looking for signs that the founder can create a system around the work. A company with rhythm is easier to back because it suggests that capital will amplify discipline, not chaos.

Leave a comment

From founder force to company operating system

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Founders often think investors are only judging the company. They assume the investor is focused on the market, the product, the science, the evidence, the traction, the team, the regulatory pathway, the financial model, and the next milestone. Investors are looking at all of those things, but they are also reading something else. They are reading the founder.

This is uncomfortable because founder energy feels personal. Most founders would rather believe that fundraising is a rational assessment of the business alone. But early-stage investing is never only about the business as it exists today. It is also about whether the person leading the company can carry it through the next phase of uncertainty.

In health, this matters even more because the journey is rarely fast or clean. Evidence takes time. Customers move slowly. Pilots stall. Procurement drags. Regulatory questions appear. Clinical studies create ambiguity. Strategic partners move carefully. Investors ask the same questions repeatedly. The market often agrees the problem is important long before it is ready to adopt, pay, reimburse, or scale.

That means investors are not only asking whether the company is interesting. They are asking whether the founder has the clarity, stamina, judgment, and emotional discipline to survive the path.

This is the founder energy trap. It happens when a founder carries the company on adrenaline instead of discipline. The founder is moving fast, taking meetings, rewriting the deck, chasing investors, responding to every advisor, adding product, following up with customers, and trying to keep the company alive through sheer force of will. From the inside, this feels like commitment. From the outside, investors may start to wonder whether the company has an operating rhythm or whether everything depends on the founder’s nervous system.

Energy matters. Investors want founders who care deeply. They want urgency, intensity, and commitment. But founder energy becomes dangerous when it replaces structure. A company cannot be built on adrenaline forever. At some point, the founder has to show that the business is not only being pushed forward by effort, but organised by discipline.

Subscribe now

Investors read the founder under pressure

Every fundraising conversation gives investors a chance to see how the founder behaves under pressure. They watch how the founder answers difficult questions. They listen to whether the founder becomes defensive, vague, calm, precise, reactive, or thoughtful. They notice whether the founder can admit risk without sounding weak. They notice whether the founder can explain uncertainty without losing conviction. They notice whether the founder has a plan, or only urgency.

This is not about personality. Different founders communicate differently. Some are intense. Some are quiet. Some are analytical. Some are charismatic. Some are technical. Some are clinical. Some are commercial. There is no single founder style that investors trust. What investors are trying to understand is whether the founder’s energy is stable enough to build around.

A founder can be passionate and still disciplined. A founder can be intense and still clear. A founder can be ambitious and still realistic. The problem begins when the founder’s energy starts to feel chaotic. The investor asks a question about the buyer, and the founder jumps to the product. The investor asks about risk, and the founder answers with vision. The investor asks about evidence, and the founder becomes defensive. The investor asks about capital use, and the founder lists activity instead of explaining value creation.

These moments matter because investors know the company will face harder moments than a pitch meeting. If the founder struggles to stay clear during fundraising, investors may wonder how they will behave when a study is delayed, a pilot does not convert, a key hire leaves, a strategic partner slows down, or the next round takes longer than expected.

Fundraising does not reveal everything, but it reveals enough to create a signal.

Adrenaline can look like momentum

The founder energy trap is difficult to spot because adrenaline can look like momentum. The founder is busy. The calendar is full. Investor conversations are happening. The team is building. The pipeline is active. The founder is posting, pitching, following up, attending events, updating materials, taking advice, and creating movement around the company.

From the outside, that can look impressive. From the inside, it can feel necessary. Early-stage companies often survive because founders push. There are moments where urgency matters. There are times when the founder needs to create energy before the market gives it back.

But adrenaline is not the same as operating discipline. A founder can be busy and still not be reducing the right risks. A company can be visible and still not be getting sharper. A founder can take many meetings and still not know which investor concerns keep repeating. A team can build quickly and still not know which product decision matters most. The company can feel alive, but still not be learning in a structured way.

This is where investors become careful. They want to know whether the founder’s energy is producing clarity or only motion. Is the company becoming more focused after each market interaction? Is the pitch improving because the founder understands the objections better? Is the product roadmap being shaped by evidence or anxiety? Is the founder choosing priorities or reacting to noise?

Adrenaline can help a founder start. Discipline is what helps the company compound.

Health punishes chaotic energy

Some markets allow founders to move quickly through mistakes. Health is less forgiving. The cost of chaotic energy is higher because the system is slower, more regulated, more evidence-driven, and more stakeholder-heavy. A founder who reacts to every conversation can easily lose months. A founder who changes direction after every advisor call can confuse the team. A founder who expands the product after every pilot discussion can increase implementation risk. A founder who chases every investor comment can blur the fundraising story.

Health founders need energy, but they also need restraint. They need to know when to push and when to wait. They need to know which feedback matters and which feedback is noise. They need to know which risk must be reduced now and which risk can be addressed later. They need to know when a delay is normal and when it is a signal that the strategy is wrong.

This is one of the reasons founder stamina matters. Stamina is not just the ability to work long hours. It is the ability to remain clear when progress is slow. It is the ability to keep making good decisions when the market does not move at the speed the founder wants. It is the ability to stay disciplined after rejection, after ambiguity, after setbacks, and after the tenth conversation that ends with “keep us updated.”

Investors know that health companies rarely move in straight lines. They are not looking for founders who never get tired or frustrated. That would be unrealistic. They are looking for founders who can build a company that is not dependent on emotional spikes. The best founders create systems, rhythms, and decision rules that allow the company to keep moving even when founder energy fluctuates.

That is a very different signal.

The company should not depend on founder force alone

At the earliest stage, every company depends heavily on the founder. That is normal. The founder sells the vision, recruits the first team, speaks to customers, raises capital, builds the narrative, manages advisors, and holds the whole thing together before the company has real structure. Founder force is part of the beginning.

But investors become concerned when founder force remains the only operating system. If every customer relationship depends on the founder, every investor update depends on the founder, every product decision depends on the founder, every strategic choice depends on the founder, and every internal rhythm depends on the founder’s personal energy, the company starts to look fragile.

This does not mean the founder should disappear from the centre of the company. Early companies need founder leadership. But leadership is not the same as carrying every part of the business personally. A founder who cannot translate energy into process eventually becomes the bottleneck.

Investors notice this in subtle ways. They ask about the team, and the founder answers as if they are still doing everything. They ask about customer learning, and all the insight sits in the founder’s head. They ask about sales, and every relationship is founder-led. They ask about execution, and the company has no clear operating cadence. They ask about priorities, and the founder gives a long list of everything happening at once.

This creates a concern that the company may only move when the founder pushes it. That may be enough for the first phase, but it is not enough for institutional capital. Investors want to see that the founder can create leverage. They want to know that the company is becoming more than one person’s intensity.

Share

Clarity is a form of energy

Founders often think energy is about passion, speed, and persistence. Those things matter, but clarity is also a form of energy. A clear founder creates momentum because people know what matters. The team knows what to focus on. Advisors know where to help. Investors know what the round is designed to prove. Customers understand the value. The company moves with less wasted motion.

A founder without clarity creates a different kind of energy. It may feel intense, but it becomes expensive. The team keeps shifting priorities. The deck keeps changing without becoming stronger. The product roadmap grows without a sharper wedge. Investor conversations create anxiety instead of insight. Customer feedback becomes noise instead of evidence.

This is why investors value founders who can simplify the company without making it shallow. A clear founder can say what matters now, what can wait, and why. They can explain the current risk, the next milestone, and the logic behind the round. They can explain why they are saying no to certain opportunities, features, markets, or partnerships. They are not calm because the company is easy. They are calm because they have organised the difficulty.

That kind of clarity gives investors confidence. It tells them the founder is not only working hard, but thinking clearly. It also tells them the company may use capital more intelligently. Capital does not solve chaos. In many cases, capital accelerates chaos. A founder who lacks clarity before the round may simply spend more money on unfocused activity after the round.

Investors know this. That is why founder clarity matters so much.

Resilience is not the same as endurance

Founders often confuse resilience with endurance. They think resilience means continuing no matter what, taking every call, working longer, pushing harder, and refusing to slow down. There is value in persistence, but endurance alone is not enough. A founder can endure for a long time and still keep making the same mistake.

Real resilience is adaptive. It is the ability to absorb reality and change intelligently. It is the ability to hear difficult feedback without collapsing or becoming defensive. It is the ability to separate rejection from information. It is the ability to preserve ambition while adjusting strategy. It is the ability to keep the company moving without pretending every signal is positive.

This is especially important in health because founders face long periods where the market gives mixed signals. A hospital may love the concept but delay adoption. An investor may like the problem but pass on the round. A pilot may generate learning but no revenue. A strategic partner may stay close but not commit. A clinician may champion the product but have no budget authority. The founder has to interpret these signals without becoming either cynical or delusional.

Investors are reading that ability. They want to know whether the founder can stay honest when the market is slow. They want to know whether the founder can keep learning when things do not convert. They want to know whether the founder can manage disappointment without losing discipline. They want to know whether the founder can remain ambitious without turning every delay into a story that hides the truth.

That is resilience. Not endless energy, but disciplined adaptation.

When founder energy becomes a red flag

Founder energy becomes a red flag when it starts to feel disconnected from evidence. The founder is excited, but the market has not responded. The founder is certain, but the data is still early. The founder is moving fast, but the customer is not moving with them. The founder is adding activity, but the company is not becoming easier to believe.

Investors may also worry when the founder seems too reactive. Every investor comment changes the pitch. Every advisor suggestion changes the roadmap. Every customer request becomes a feature. Every slow conversation creates a new strategy. This kind of reactivity can be exhausting for the team and confusing for the market. It also suggests the founder may not yet have enough internal conviction to filter external noise.

Another red flag is when the founder cannot distinguish urgency from panic. Urgency has focus. Panic has motion. Urgency says, “This is the risk that matters now, and this is how we are reducing it.” Panic says, “We are doing everything because everything feels important.” Investors can usually tell the difference.

The strongest founders do not need to look calm all the time. Startups are hard. Fundraising is emotional. Health is slow. But they do need to show that their energy is being converted into disciplined company building. Investors are not looking for perfect emotional control. They are looking for leadership that can survive pressure without becoming chaotic.

The founder’s operating rhythm

The deeper question investors are asking is whether the founder has an operating rhythm that can support the next stage of the company. A founder can push hard for a few months on adrenaline, but a health company may take years to build. That means the founder needs a rhythm that allows learning, execution, decision-making, and communication to continue without depending entirely on emotional intensity.

A strong operating rhythm usually shows up in how the founder runs the company. There is a clear sense of priorities. There is a disciplined way of reviewing customer learning. Investor feedback is captured and interpreted rather than emotionally absorbed. Product decisions connect to evidence. Team meetings are not just updates, but places where the company decides what matters. The founder can explain what has changed, what has been learned, what still needs to be proven, and what the company is doing next.

This does not require a large team or heavy process. Early companies should not become bureaucratic. But even small teams need rhythm. Without rhythm, the company becomes dependent on founder urgency. With rhythm, the company starts to compound.

This matters in fundraising because investors are not only funding the next set of activities. They are funding the founder’s ability to turn capital into progress. If the founder has no operating discipline before the round, the investor may worry that more capital will create more activity without enough value creation. If the founder can show a clear rhythm, investors can believe that capital will be used with intention.

The founder’s rhythm also affects communication. Investors trust founders who can communicate consistently without drama. They do not need every update to be positive. They need the founder to be clear. What happened? What did the company learn? What changed? What remains difficult? What is the next decision? A founder who can communicate this way signals control even when the company is still early.

This is where founder energy becomes part of the investment case. Investors know the plan will change. They know the market will push back. They know health timelines will test the company. They want to believe the founder will remain disciplined through that process. Not because they are calm by nature, but because they have built habits that keep the company honest.

The best founders do not carry the company on adrenaline alone. They build a rhythm that turns energy into execution. They create systems that help the company learn from the market, focus on the right risks, and communicate progress clearly. They do not wait until after the round to become disciplined. They show discipline before the round, so investors can believe the next round of capital will amplify the right behaviour.

This is why founder energy is not a soft issue. It is not separate from the company. It affects hiring, fundraising, customer conversations, product decisions, investor trust, and the way the company handles setbacks. In a long, difficult market like health, founder energy becomes visible because the company cannot hide behind speed forever.

The founder who looks energetic but chaotic creates concern. The founder who looks exhausted but disciplined may still be trusted. The founder who combines urgency with clarity, resilience with honesty, and ambition with operating discipline is much easier to back.

Leave a comment

Final thought

Founder energy matters, but not in the way many founders think. Investors are not looking for endless enthusiasm. They are looking for sustainable leadership.

They want to see a founder who cares deeply, but does not confuse intensity with progress. They want to see urgency, but not panic. They want to see ambition, but not denial. They want to see resilience, but not blind endurance. They want to see a founder who can move through slow markets, difficult feedback, delayed adoption, investor rejection, and operational pressure without losing clarity.

This matters because health companies are not built in one burst of energy. They are built through long periods of uncertainty. The founder has to keep the company alive, but also make it sharper. They have to create momentum, but also make good decisions. They have to absorb feedback, but also filter it. They have to lead with conviction, but also remain honest about what is not yet working.

That is the balance investors notice.

The founder energy trap is believing that more intensity will solve what only discipline can solve. It will not. Intensity can start the company, but discipline is what makes the company investable.

In health, where the path is long and the pressure is real, investors are not only asking whether the founder can push.

They are asking whether the founder can last.

HealthVC Summit Founders Day

This is also one of the reasons we are building HealthVC Summit Founders Day in Zurich on 3 September 2026.

Founders Day is designed for healthtech and life science founders who want to move beyond passive networking and get into the right rooms with investors and strategic partners. We are curating a maximum of 100 founders, with pre-scheduled investor meetings, sector-focused showcase opportunities, and conversations around market access, partnerships, capital, and international growth across Europe, China, and Saudi Arabia.

The goal is simple: help serious founders build better companies, create real partnerships, and meet the people who can help them move forward.

Founder applications are now open:

https://www.healthvcsummit.com/

P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Subscribe now and operate like a pro.

Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Until next time, keep venturing forward!

Subscribe now

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most underestimated skills in fundraising is translation. Not translation between languages, but translation between decision-makers. Founders often explain the company in the language they are most comfortable with. Scientific founders explain the science. Clinical founders explain the patient need. Product founders explain the features. Commercial founders explain the market. Technical founders explain the architecture, data, model, or platform.

That is natural. Founders usually build from the world they understand best. The problem is that the people they need to convince do not all think from that same world. Investors do not think like clinicians. Clinicians do not think like procurement. Procurement does not think like strategic partners. Strategic partners do not think like founders. Boards do not think like product teams. Each group is trying to answer a different question before they say yes.

This is the boardroom translation problem. A founder can understand the company deeply, but still fail to translate it into the decision language of the person in front of them. The company may be strong, the problem may be real, and the opportunity may be meaningful, but if the explanation is trapped inside the founder’s preferred language, the audience may not know how to act.

This matters because health companies are rarely bought, funded, adopted, or partnered by one person. They move through rooms. Investor partner meetings. Hospital budget meetings. Procurement reviews. Clinical committees. Regulatory discussions. Strategic partnership reviews. Board meetings. Investment committees. The company needs to make sense in all of those rooms, especially when the founder is not there to explain it again.

A founder who cannot translate the company forces every stakeholder to do extra work. The investor has to translate the company for the partnership. The clinician has to translate it for administration. The innovation team has to translate it for procurement. The strategic partner has to translate it for business development, legal, commercial, and leadership. That slows everything down.

The best founders do not only explain what the company does. They explain it in the language of the decision that needs to be made.

Subscribe now

The same company has many different meanings

A health company does not mean the same thing to every stakeholder. To a clinician, the company may represent better care, less friction, faster diagnosis, improved workflow, or a reduction in patient risk. To a hospital executive, it may represent operational efficiency, quality improvement, staff capacity, compliance, budget impact, or institutional differentiation. To a payer, it may represent cost avoidance, evidence quality, risk reduction, or measurable outcomes. To a strategic partner, it may represent pipeline relevance, market access, distribution, data, technology leverage, or long-term competitive advantage.

To an investor, the company means something else again. It represents a risk profile, a financing path, a value creation opportunity, a future round, a possible exit, and a question of whether capital can turn current uncertainty into future value. The investor may care about the clinical problem, but they are also asking whether the company can build enough evidence, access the right market, protect its position, attract future capital, and create a return.

This is why founders get frustrated. They think they are explaining the company clearly, but they are often explaining it from the wrong angle for the room they are in. A founder may give a highly technical explanation to an investor who is trying to understand market entry. They may give a patient-impact explanation to a hospital finance team that is trying to understand budget ownership. They may give a product demo to a strategic partner who is trying to understand why the company matters to their corporate priorities.

The content may be true, but truth alone is not enough. The audience needs to understand why the truth matters to them.

This does not mean the founder should manipulate the story or tell different versions that contradict each other. The company should remain consistent. The problem, product, evidence, market, and milestone should not change from room to room. What changes is the framing. The founder needs to know which part of the company matters most to each decision-maker and explain the opportunity through that lens.

Translation is not changing the truth. It is making the truth usable.

Founder language is not always decision language

Founder language is often full of vision, history, intensity, and personal conviction. The founder explains why they started, how they discovered the problem, what they have built, what they believe the future should look like, and why the company matters. That can be powerful because founders need conviction. A company without founder conviction is hard to believe.

But founder language can also become too internal. It can include too much backstory, too many assumptions, too many emotional shortcuts, and too much context that the audience has not yet earned. The founder has lived with the problem for years, so they forget what a new listener needs first. They jump into the product before the problem is clear. They explain future scale before the first use case is understood. They talk about the mission before the buyer is defined. They describe the platform before the audience understands why the first wedge matters.

Decision-makers do not have the founder’s context. They need a clearer path into the company. They need to understand the problem in their own terms, the consequence of not solving it, the evidence that the solution matters, and the decision being asked of them.

This is why founder language often works better in origin stories than in boardrooms. It can create emotional connection, but it may not create action. A boardroom needs a decision. An investor meeting needs conviction. A hospital meeting needs operational logic. A strategic partnership meeting needs relevance. A procurement review needs risk control. A clinical committee needs evidence and workflow fit.

The founder’s job is to carry the conviction without forcing the audience to decode the company from the founder’s perspective.

Scientific language can impress without converting

Scientific language is one of the most common traps in health fundraising. A founder with deep scientific expertise may explain the mechanism, the data, the technical novelty, the biology, the model, the platform, the analytical method, or the research history in detail. This can be impressive, especially when the science is genuinely strong. But scientific strength does not automatically translate into investment clarity.

Investors may respect the science and still not understand the company. They may believe the mechanism is interesting but still wonder which indication comes first. They may understand that the platform is technically differentiated but still not know what the next financing milestone proves. They may see that the data is promising but still ask whether it changes the risk profile enough to justify the round.

Scientific founders sometimes believe more technical detail will create more confidence. Sometimes it does, particularly with specialist investors or scientific advisors. But in many fundraising conversations, too much scientific detail too early can create distance. The investor may not need a deeper explanation of the mechanism at that moment. They may need to understand why the mechanism creates a company.

The science has to be translated into value creation. What does the science make possible? What risk has already been reduced? What risk remains? What evidence is needed next? Who cares if this works? Why does this round matter? How does the company become more valuable if the next milestone is achieved?

That is the translation investors need.

The goal is not to make the science shallow. It is to make the business around the science legible. The best scientific founders can go deep when needed, but they do not start by making the investor prove they can keep up. They start by making the investment case clear enough that the technical depth has somewhere to land.

Clinical language does not always reach the buyer

Clinical founders often speak in the language of patient need, clinical workflow, physician frustration, care quality, and unmet need. That language is essential because health companies must solve real problems. If the product does not matter clinically, the company may not deserve to exist. Clinical insight gives founders credibility and helps them avoid building products that make sense in theory but fail in practice.

But clinical language can fail when the audience is not making a purely clinical decision. A doctor may understand why the product matters, but a hospital executive may ask how it affects budget, capacity, risk, staff time, quality metrics, or strategic priorities. Procurement may ask about vendor risk, implementation, contract terms, IT requirements, and liability. A payer may ask whether the product reduces cost, improves outcomes, or changes utilisation in a measurable way.

The clinical case may be necessary, but it is not always sufficient.

This is where many health founders lose momentum. They have strong clinical support, but they cannot translate that support into institutional action. They can explain why the product should be used, but not why it will be bought. They can explain why patients benefit, but not who pays. They can explain why the workflow is broken, but not what operational owner has the incentive and authority to fix it.

The best founders do not abandon clinical language. They connect it to decision language. They show how the clinical problem creates operational burden, financial cost, quality risk, compliance pressure, capacity strain, or strategic urgency. They help non-clinical stakeholders understand why the clinical issue matters to their decision.

That is how clinical value starts to move through the system.

Product language is not enough for investors

Product founders often explain what the product does. They show dashboards, workflows, features, user journeys, AI layers, integrations, reports, alerts, and modules. They demonstrate functionality because functionality is visible. A good demo can create excitement. It can make the company feel real. It can help investors understand how the product works.

But investors are not only asking what the product does. They are asking what the product proves.

A product may have many features, but the investor wants to know which feature creates value. A dashboard may look polished, but the investor wants to know who uses it, how often, and what decision it changes. An AI layer may sound advanced, but the investor wants to know whether it reduces risk, improves performance, or creates defensibility. An integration may look important, but the investor wants to know whether it is essential for adoption or just another implementation burden.

Product language can become too focused on capability. Investors need capability translated into evidence, adoption, buyer urgency, defensibility, and value creation. The question is not only whether the product can do something. The question is whether that thing matters enough for someone to change behaviour, pay, adopt, renew, expand, partner, or invest.

This is why product-led explanations can underperform in fundraising. The founder shows the product, but the investor still cannot see the business. The investor may like the interface and still wonder who buys. They may understand the workflow and still wonder how hard it is to implement. They may see the features and still wonder whether the company has a focused wedge.

The strongest founders use product language only after the decision context is clear. They show the product as proof of a specific business argument. The demo is not a tour. It is evidence.

Share

Investors need investment language

When founders speak to investors, the company needs to be translated into investment language. That does not mean using buzzwords or pretending everything is about exit multiples. It means explaining the company in terms of risk, evidence, milestones, capital, market entry, defensibility, future financing, and value creation.

Investors need to understand what risk they are being asked to take. They need to know why that risk is acceptable at this stage. They need to see what has already been proven and what remains uncertain. They need to understand what this round of capital is designed to change. They need to believe that if the company achieves the next milestone, the company will be more valuable, more fundable, more partnerable, or more strategically relevant.

This is often where founders struggle. They explain the company as a product or mission, but not as an investment. They talk about what they will build, but not what that build proves. They talk about market size, but not market entry. They talk about pilots, but not conversion. They talk about future potential, but not the sequence of value creation.

Investment language is not cold. It is simply the language investors need to make a decision. It helps the investor understand why the company deserves capital now and what the company should become after that capital is used.

A founder who can speak investment language does not stop being authentic. They become easier to underwrite.

Hospitals need institutional language

Hospitals do not make decisions in founder language either. A founder may see the hospital as a customer, but the hospital sees itself as an institution with constraints. It has budgets, staff shortages, compliance requirements, patient safety standards, IT systems, procurement processes, operational priorities, and political realities. Even when the clinical need is obvious, the institution still has to decide whether it can absorb the solution.

This means the company needs to be translated into institutional language. What does this product reduce, improve, protect, simplify, or enable for the hospital? Does it reduce workload? Does it improve patient flow? Does it support compliance? Does it create measurable quality improvement? Does it reduce avoidable cost? Does it help staff operate better? Does it fit existing systems? Does it create risk or reduce risk?

A founder who only explains the product’s clinical benefit may struggle to move the hospital. The clinical benefit matters, but adoption often depends on whether the institution can justify the decision across multiple stakeholders. The founder needs to help the hospital see the product not only as a clinical tool, but as an institutional decision.

This is difficult because hospitals contain many internal languages. Clinicians speak one language, IT another, finance another, compliance another, procurement another, and leadership another. The founder does not need to become an expert in every internal function, but they do need to understand that each function has its own concerns.

A product that cannot be translated across those concerns may remain liked but not adopted.

Strategic partners need strategic language

Strategic partners also need a different translation. A pharma company, medtech company, diagnostics group, insurer, corporate health player, or large healthcare organisation may be interested in innovation, but they are rarely interested in innovation in the abstract. They want to understand how the startup connects to their priorities.

A founder may explain the product as a solution to a market problem. A strategic partner may ask how it strengthens their pipeline, improves market access, creates a data advantage, supports distribution, opens a new category, complements an existing asset, reduces development risk, or helps them serve a customer segment they already care about. The same company may need to be framed differently depending on the strategic partner’s context.

This is where founders often overestimate partnership interest. They get a positive conversation with a strategic, but they do not translate the company into the strategic’s decision language. The founder explains why the company is exciting. The strategic partner is asking whether the company is relevant.

Relevance is not the same as excitement. A strategic partner may think the technology is impressive and still not see why it matters to their current priorities. They may admire the founder and still not know where the company sits inside their organisation. They may believe the category is important but have no internal owner for the relationship.

The best founders do the translation work before the meeting. They understand the strategic partner’s business, priorities, pressures, portfolio, and likely decision logic. They explain not only what the startup does, but why it could matter to that partner now.

Boards need decision language

Boards need yet another translation. A board is not there to receive every detail. It is there to help make better decisions. Founders often use board meetings to report activity, but boardrooms need clarity around choices, tradeoffs, risks, capital allocation, hiring, runway, milestones, and strategic direction.

This is especially important as companies mature. The founder may be deep in daily execution, but the board needs to understand what decisions matter. Should the company narrow the market? Should it delay hiring? Should it extend runway? Should it pursue a strategic partnership? Should it raise now or later? Should it focus on evidence, product, revenue, regulation, or team? What tradeoff is being made and why?

A founder who cannot translate operating complexity into decision language may have ineffective board meetings. The board hears updates but does not know where to help. The founder may leave with comments, but not decisions. The company loses the chance to use the board properly.

Boardroom translation is about turning information into judgment. What changed? What matters? What decision is needed? What are the options? What is the recommendation? What risk does the company accept if it chooses this path?

This same skill helps in fundraising because investors are also listening for decision quality. They want to know whether the founder can turn complexity into choices.

P.S. Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

The founder as translator

Read more

We’re partnering with TechBBQ 2026.

We’re excited to announce that HealthVC/Clarma Capital is partnering with TechBBQ 2026, taking place on 26–27 August at Bella Center Copenhagen.

TechBBQ brings together 10,000+ attendees, 1,500+ investors, 3,000+ startups, and 340+ speakers for two days focused on startups, capital, innovation, and the future of the European ecosystem.

Known as the home of founders, builders, and bold ideas, TechBBQ is where the people building and backing the next generation of companies come together.

For us, this partnership is about being part of the room where real conversations happen, connections are made, and new opportunities begin.

At HealthVC, we care about helping founders build better companies, understand capital, and connect with the investors and partners who can help them grow.

We look forward to joining the TechBBQ community in Copenhagen this August.

Join us at TechBBQ 2026
26–27 August
Bella Center Copenhagen

Tickets are limited:
https://techbbq.dk/buy-tickets/

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Some startups are not rejected because the opportunity is bad. They are rejected because the company is too hard to understand.

This happens more often than founders realise. The founder may be working on a serious problem. The product may be useful. The science may be strong. The market may be large. The team may be credible. The company may even have early traction, clinical interest, pilot activity, or strategic conversations. But when the founder explains the business, the story does not land. The investor cannot clearly understand what the company does, who it serves, why it matters now, what has been proven, what still needs to be proven, and why this round of capital changes the company’s value.

That is a problem because investors do not invest in what they cannot understand well enough to defend.

A founder may believe the investor should spend more time trying to understand the company. They may think the complexity is obvious because they live inside it every day. They may assume that once the investor sees the product, reads the deck, joins another call, or reviews the data room, the opportunity will become clear. Sometimes that is true. But often the issue is not lack of information. The issue is lack of clarity.

This is the company that cannot explain itself. It is not necessarily a bad company. It may be an early company, a technical company, a scientific company, a platform company, or a company operating in a difficult market. But if the founder cannot explain the problem, buyer, product, evidence, market, milestone, and investment case clearly enough, the company becomes difficult for investors to carry internally.

Clarity is not a cosmetic layer on top of fundraising. It is part of the investment case. A founder who can explain the company clearly signals that they understand the company deeply. A founder who cannot explain the company clearly creates doubt, even when the opportunity itself may be strong.

Subscribe now

Confusion creates investor friction

Investors are not only listening for excitement. They are listening for structure. They are trying to understand what kind of company this is, what risk they are being asked to underwrite, what evidence exists today, and what needs to happen next. If the founder makes that difficult, the investor has to work too hard before conviction can form.

This friction matters because investors see many companies. They are constantly deciding where to spend time, which opportunities deserve deeper work, which companies are ready for diligence, and which stories can be discussed with partners or investment committees. A company that is difficult to understand may not always receive the time needed to decode it.

The founder may think the investor has missed the point. In reality, the founder may not have made the point clearly enough.

In health, this is especially important because the underlying businesses can already be complex. There may be science, clinical validation, regulation, reimbursement, workflow change, data protection, procurement, behaviour change, and market access. Investors do not expect health companies to be simple, but they do expect the founder to make the complexity understandable. If the founder adds narrative confusion on top of business complexity, the company becomes harder to believe.

A clear explanation does not remove risk. It organises risk. It helps the investor understand which risks matter, which risks have been reduced, which risks remain, and why the next milestone is worth funding. That is why clarity is so valuable. It does not make the company less ambitious. It makes the ambition easier to underwrite.

The founder understands too much

One of the reasons companies become hard to explain is that the founder understands too much. This sounds strange, but it is common. The founder has spent months or years living inside the problem. They know the history, the edge cases, the product decisions, the scientific nuance, the customer feedback, the market context, the regulatory details, the investor objections, and every possible future direction.

Because the founder sees the whole picture, they often try to explain too much at once. They include every use case, every stakeholder, every feature, every market, every possible buyer, and every long-term application. The result is not a richer story. It is a heavier one.

Investors do not need the whole company at once. They need the entry point. They need to understand the first thing that matters. What is the problem? Who has it? Why does it matter now? What does the product change? What evidence supports that claim? Who pays? What does this round prove? If those questions are not clear, the rest of the detail becomes noise.

This is one of the hardest shifts for founders. Clarity often requires leaving things out. Not because they are irrelevant forever, but because they are not the first thing the investor needs to believe. A platform may have many future applications, but the investor still needs to understand the first wedge. A scientific company may have deep technical nuance, but the investor still needs to understand the first value inflection. A healthtech product may support many stakeholders, but the investor still needs to know who the initial buyer is.

The strongest founders know how to simplify without making the company shallow. They do not strip away the complexity. They sequence it.

The pitch has to travel

A founder is not only explaining the company to the person on the call. They are giving that person the language needed to explain the company to someone else. This is one of the most important parts of fundraising.

Your investor champion needs to carry the story internally. They may need to explain it to a partner. They may need to discuss it in a Monday meeting. They may need to write a memo. They may need to defend the deal to an investment committee. They may need to bring in advisors, co-investors, clinical experts, regulatory consultants, or strategic partners.

If the company is difficult to explain, the investor has to become the translator. That is a risky position for the founder. The investor may like the opportunity, but if they cannot explain it clearly to others, the deal becomes harder to move forward.

This is where many founders underestimate the importance of narrative discipline. They think the pitch is only about creating excitement in the first meeting. It is not. The pitch also needs to survive when the founder is not in the room. The story has to be clear enough that someone else can repeat it accurately, defend it under pressure, and explain why it matters.

A company that can be explained clearly is easier to share. A company that is easier to share is easier to discuss. A company that is easier to discuss is easier to diligence. A company that is easier to diligence is easier to fund.

That does not mean the story should be simplistic. It means the core logic should be strong enough to travel.

The problem is often not the deck

When founders struggle to explain the company, they often assume the deck needs to be redesigned. Sometimes it does. A clearer structure, better visuals, sharper slides, and better sequencing can help. But the deeper issue is often not the deck. It is the thinking beneath the deck.

If the founder cannot explain the company in a clear conversation, the deck will not fix the problem. It may make the company look more polished, but it will not make the strategy clearer. The investor may still struggle to understand the buyer, the market entry, the evidence, the milestones, or the business model.

This is why fundraising materials often expose founder confusion. A deck that tries to explain too many things usually reflects a company that has not made enough choices. Too many market slides may hide the fact that the first market is unclear. Too many product slides may hide the fact that the core use case has not been proven. Too many traction slides may hide the fact that the traction is not yet strong enough. Too many future applications may hide the fact that the first wedge is weak.

A good deck is not a collection of information. It is a sequence of belief. It should help the investor move from problem to solution, from solution to evidence, from evidence to market, from market to milestone, and from milestone to investment logic. If the founder cannot create that sequence, the investor may leave the meeting with interest but not conviction.

The goal is not to make the company sound simple. The goal is to make the investment case coherent.

Share

Health founders often speak in the wrong language

Another reason companies fail to explain themselves is that founders speak in the wrong language for the audience. Scientific founders often speak in scientific language. Clinical founders speak in clinical language. Product founders speak in product language. Commercial founders speak in sales language. Each language has value, but investors need the company translated into investment language.

Investment language does not mean hype. It means explaining the business through the questions investors are trying to answer. What risk exists today? What evidence reduces that risk? What does this round prove? Why does that proof matter? Who will care if the company succeeds? What makes the company more valuable after the next milestone?

A scientific explanation may show why the technology is impressive, but it may not explain why the company is fundable. A clinical explanation may show why the product is needed, but it may not explain who pays. A product explanation may show what the tool can do, but it may not explain why adoption will happen. A market explanation may show that the problem is large, but it may not explain the first customer.

This translation matters because investors are not only evaluating whether the company is meaningful. They are evaluating whether it can become valuable. That requires the founder to connect the product, market, evidence, team, and financing plan into one clear story.

The best founders can move between languages. They can explain the science to scientists, the workflow to clinicians, the value to buyers, and the investment case to investors. They do not force every audience to interpret the company through the founder’s preferred language.

Clarity is a sign of strategic maturity

Investors often treat clarity as a signal. A founder who can explain the company clearly usually understands the company better than a founder who needs twenty minutes to reach the point. Clear founders have usually made hard choices. They know what matters now and what can wait. They know the difference between the long-term vision and the current financing milestone. They know which risks are central and which are secondary.

This is why clarity feels like maturity. It shows that the founder has moved beyond raw possibility and into strategic discipline. They are not trying to make the company sound bigger by adding more use cases, more markets, more stakeholders, more features, and more future options. They are making the company more investable by showing where value begins.

This does not mean every clear company is a good investment. It also does not mean every complex company is bad. But a clear company is easier to evaluate. Investors can understand the assumptions. They can test the evidence. They can discuss the risks. They can see what the next round of capital is designed to change.

A company that cannot explain itself makes all of that harder. Investors may still be interested, but they will have to spend more energy just to understand what they are looking at. In a competitive fundraising market, that is not a small problem.

Clarity gives the founder an advantage because it reduces unnecessary friction. It lets investors spend their energy evaluating the opportunity rather than decoding the story.

The milestone is where clarity often breaks

One of the places where unclear companies struggle most is the milestone. The founder may be able to explain the product and the market, but when asked what the next round of capital actually proves, the answer becomes vague.

They say the money will be used to build the team, continue product development, run pilots, expand the market, strengthen partnerships, generate evidence, and prepare for the next phase. Some of that may be true, but it does not explain the value creation logic. Investors need to know what the company will become after the round that it is not today.

This is where clarity matters most. A milestone should not be a list of activities. It should be a change in the company’s risk profile. What will investors believe after this round that they cannot believe today? What evidence will exist? What decision will be made easier? What risk will be reduced? What next investor, customer, partner, or acquirer will care?

If the founder cannot explain that, the round becomes harder to fund. The company may need money, but investors do not fund need. They fund progress. They fund the possibility that today’s uncertainty can become tomorrow’s value.

A clear milestone gives investors something to underwrite. It tells them why this financing matters and what success looks like. An unclear milestone makes the company feel like it is raising to keep going rather than raising to become more valuable.

Leave a comment

Making the company easier to carry

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most underrated weaknesses in early-stage companies is not a lack of effort. It is a lack of memory.

Founders speak to customers, clinicians, advisors, investors, operators, consultants, strategic partners, pilot sites, hospital teams, pharma contacts, payers, and other founders. They collect feedback constantly. They hear objections, patterns, warnings, signals, requests, frustrations, and moments of real market insight. The company is learning every week, sometimes every day.

But too much of that learning stays inside the founder’s head.

A customer says something important on a call. An investor challenges the same part of the story three times. A clinician explains why the workflow will not change. A hospital contact reveals who really owns the budget. An advisor points out a regulatory risk. A pilot partner gives feedback that should shape the next milestone. The founder understands it in the moment, maybe even repeats it to the team later, but then the company moves on. The insight is not captured properly. It is not turned into a strategy. It is not turned into evidence. It is not turned into product direction, sales discipline, fundraising language, or operating decisions.

This is the founder's memory problem.

The company is hearing the market, but not storing what it learns in a way that changes the company.

That matters because early-stage companies are not only built by doing things. They are built by learning from what happens when they do those things. Every customer call, investor meeting, advisor conversation, pilot discussion, and partnership meeting should make the company sharper. The problem is that many founders are exposed to useful information constantly, but the learning remains informal, scattered, and founder-dependent.

The result is a company that keeps having conversations but does not compound insight.

Subscribe now

Conversations are not learning unless the company changes

Founders often confuse activity with learning. They say they have spoken with thirty customers, met twenty investors, had ten advisor conversations, and explored several pilots. That may sound productive, but the real question is what the company learned and what changed because of it.

A customer call is only useful if it clarifies the problem, buyer, workflow, urgency, budget, objection, or adoption path. An investor call is only useful if it reveals how the market is interpreting the company, where the story is unclear, which risks are not yet believed, or what evidence is missing. An advisor conversation is only useful if it helps the founder make a better decision. A pilot discussion is only useful if it teaches the company what must be true for adoption, implementation, conversion, or expansion.

The danger is that founders can have a lot of conversations without building a better company. They collect comments, but not conclusions. They gather opinions, but not patterns. They remember anecdotes, but not evidence. They leave meetings with a feeling that the market is interested, but not a precise understanding of what the market is actually saying.

This becomes a problem in fundraising because investors do not only ask whether founders have spoken to the market. They ask what those conversations proved. If the founder cannot explain the pattern clearly, the number of conversations matters less. Thirty customer calls that do not clarify the buyer, the pain, the budget, or the adoption path are not strong evidence. They are activity.

The best founders do not treat conversations as proof by themselves. They treat conversations as raw material. They capture what they heard, compare it across stakeholders, identify repeated patterns, separate signal from noise, and then make decisions. That is how learning becomes strategy.

The founder becomes the bottleneck for insight

In the earliest days of a company, it is normal for most learning to sit with the founder. The founder is taking the calls, hearing the objections, adjusting the pitch, interpreting the feedback, and making decisions in real time. That is part of the job. Early companies move through founder intensity.

But as the company develops, this becomes risky. If the founder is the only person who remembers why certain decisions were made, what customers really said, which investor objections keep repeating, what the pilot partner cared about, or why one market was chosen over another, the company becomes dependent on the founder's memory. The team cannot learn properly because the learning is not visible. New hires cannot understand the market quickly because the insight is not organised. Advisors repeat old advice because they do not see what has already been tested. Investors hear claims without the underlying evidence.

This is one of the hidden reasons early companies become inefficient. The founder keeps carrying the context personally. Every new discussion requires the founder to re-explain the market. Every strategic decision depends on what the founder remembers. Every investor update has to be rebuilt from memory. Every product debate returns to old conversations because the company has no shared source of truth.

A founder’s memory is not an operating system.

It may work for a while, especially when the company is very small. But it does not scale. As the company raises capital, hires people, runs pilots, manages advisors, builds product, and speaks to investors, the learning needs to become institutional. The company needs a way to remember what the market has taught it so that insight can compound.

This is not about bureaucracy. It is about discipline. If the company does not capture learning, it keeps paying for the same lessons again.

Investor feedback is often wasted

One of the biggest areas where founders lose value is investor feedback. Fundraising creates a huge amount of information. Every investor conversation tells the founder something about how the company is being perceived. Some investors misunderstand the story. Some focus on the same risk. Some ask the same question in different ways. Some react strongly to one part of the company and ignore another. Some pass because of fund fit, but others pass because the company has not yet answered a real concern.

Founders often leave these calls emotionally rather than analytically. A good call creates optimism. A bad call creates frustration. A pass creates disappointment. A positive follow-up creates energy. But the deeper value is in the pattern. What did investors consistently not understand? Where did they slow down? What did they challenge? What did they believe quickly? What did they discount? Which questions kept coming back?

If this feedback is not captured, the founder may keep repeating the same fundraising mistake. The deck gets adjusted superficially, but the underlying issue remains. The founder changes a phrase but does not change the logic. The company keeps hearing that the market entry is unclear, the evidence is too early, the buyer is not well defined, the platform story is too broad, or the use of funds does not connect to value creation. But because the feedback is not organised, it feels like an isolated investor opinion rather than a pattern.

This is dangerous because investors are not always good at explaining exactly why they are uncomfortable. Sometimes they ask questions about the real concern rather than naming it directly. It is the founder’s job to interpret the pattern. If five relevant investors hesitate around the same part of the story, that is not noise. That is market feedback.

The best founders treat fundraising as a learning process, not just a capital process. Even when they do not get the cheque, they extract insight from the conversation. They use investor feedback to sharpen the narrative, improve the data room, refine the milestone plan, and understand what the next round will need to believe.

Leave a comment

Customer learning disappears too easily

The same problem happens with customers and users. A founder may have dozens of conversations with clinicians, hospital leaders, patients, payers, pharma teams, or operational staff, but the learning stays too fragmented. One conversation reveals a workflow pain. Another reveals a budget issue. Another reveals a reason the product would not be adopted. Another reveals that the user and buyer are not the same person. Another reveals that the problem matters, but not enough to become a priority this year.

Each insight matters, but only if the company connects them.

Without a disciplined memory, the founder may overvalue the positive signals and forget the uncomfortable ones. The clinician who loved the product is remembered. The procurement concern is softened. The pilot interest is repeated in the deck. The lack of budget is treated as a later issue. The company remembers what creates momentum and forgets what creates friction.

This is human. Founders are trying to survive. They need energy. They need optimism. They need to keep moving. But selective memory can weaken the company. If the same objection appears across multiple customer conversations and the founder does not capture it properly, the product roadmap may move in the wrong direction. If budget concerns appear early and are ignored, the commercial model may be built on wishful thinking. If workflow resistance appears repeatedly and is not documented, the company may later discover that adoption is harder than expected.

In health, this is especially important because customer feedback often contains hidden complexity. A clinician may be describing workflow risk. A finance stakeholder may be describing budget priority. An IT contact may be describing the integration burden. A compliance person may be describing institutional risk. These comments may sound operational, but they often reveal whether the product can actually be adopted.

If the company forgets those signals, it will build around a version of the market that does not exist.

The company needs a learning discipline

A founder does not need a complicated system to solve this problem, but they do need a discipline. The goal is not to turn every conversation into a report. The goal is to make sure important learning does not disappear.

The discipline starts with capturing what was actually learned, not just what was said. This distinction matters. A transcript is not insight. A meeting note is not a strategy. The founder needs to ask what the conversation revealed about the problem, buyer, urgency, evidence, pricing, adoption, risk, milestone, or fundraising story. The value is not in recording everything. The value is in interpreting what matters.

The second part is pattern recognition. One comment may be noise. Repeated comments become evidence. If multiple clinicians describe the same workflow barrier, that matters. If multiple investors struggle with the same part of the story, that matters. If multiple buyers avoid pricing, that matters. If multiple pilot sites show interest but no budget, that matters. If multiple advisors disagree, the founder needs to understand whether the disagreement is contextual or strategic.

The third part is decision-making. Learning is only useful if it changes something. It may change the pitch, the product, the roadmap, the evidence plan, the target customer, the fundraising strategy, the hiring plan, or the next milestone. It may also confirm that the company should not change direction yet. Either way, the founder should be able to explain how market learning is being turned into company action.

This is what investors want to see. They want to know that the founder is not only collecting conversations but also becoming sharper because of them. A company that learns quickly is more investable than a company that simply works hard.

Share

Memory creates better fundraising materials

One of the most practical benefits of founder memory is that it makes fundraising materials stronger. A company that captures learning properly can build a better deck, a better data room, better investor updates, and better diligence answers because the evidence is not being reconstructed from memory at the last minute.

When customer conversations are captured well, the market section becomes more specific. The founder can explain who feels the pain, why it matters, how often it appears, who controls the budget, and what adoption barriers exist. When investor feedback is captured well, the fundraising narrative becomes sharper. The founder can see which claims are confusing, which risks need better explanation, and which parts of the story create conviction. When pilot learning is captured well, the traction section becomes more credible because the founder can explain what was tested, what was learned, and what still needs to be proven.

This is how insight becomes evidence.

Too many founders treat the data room as a place to upload documents after the fact. But the best fundraising materials are built from disciplined learning over time. The deck should reflect what the company has learned from the market. The data room should support the claims made in the story. The investor update should show progress against the risks that matter. The milestone plan should reflect what the company has learned about what needs to become true next.

A founder who has captured learning can answer investor questions with confidence because the answers are grounded in real conversations and real patterns. A founder who has not captured learning often answers from memory, and memory becomes vague under pressure.

The market is teaching you what to build

The market is always teaching the founder something. It teaches through enthusiasm, hesitation, delay, objections, confusion, silence, budget resistance, feature requests, pilot friction, investor questions, advisor disagreement, and customer behaviour. The challenge is that the market rarely teaches in a clean way. It does not hand the founder a strategy. It provides signals, and the founder has to interpret them.

This is why founder memory matters. If the company does not remember the signals, it cannot interpret the pattern. If it cannot interpret the pattern, it cannot make better decisions. It may keep building what the founder wants to build instead of what the market is showing it needs. It may keep selling to the wrong stakeholder. It may keep targeting the wrong use case. It may keep pitching the wrong story to investors.

The best founders understand that strategy is not only created in a planning session. It is built from what the company learns through contact with the market. The market may teach that the buyer is different from the user. It may teach that the strongest use case is narrower than expected. It may teach that the product is valuable, but only if implementation is simpler. It may teach that investors do not understand the platform until the first wedge is explained. It may teach that the company needs more evidence before the next round.

Those lessons are expensive. The founder should not have to learn them twice.

P.S. Don’t forget to check out HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Turning learning into company advantage

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the easiest mistakes for a founder to justify is building more product. It feels productive. It feels strategic. It feels like progress. A new dashboard gets added. A new module gets scoped. A new workflow gets supported. A new AI layer gets introduced. A new service wrapper is built around the product. Another feature is added because a clinician mentioned it, an advisor suggested it, a pilot customer asked for it, or the founder believes it will make the company look more complete.

From the inside, this can feel like the company is becoming stronger. The product looks more impressive. The demo becomes broader. The deck has more screenshots. The platform feels more substantial. The founder can point to more capability, more functionality, and more use cases. It becomes easier to say the company is building something big.

But investors often see something different.

They do not automatically treat more product as more progress. In many cases, more products make the company harder to understand, harder to underwrite, and harder to believe. Not because product development is bad, but because too much product too early can hide the fact that the founder has not yet proven which part of the business actually matters.

This is the overbuilt startup problem. It happens when founders keep building around the uncertainty instead of moving through it. They expand the product before they have proven the smallest valuable wedge. They add complexity before they have proven urgency. They build a platform before they have proven the first repeatable use case. They create more surface area before they know which part of the company customers, users, buyers, partners, or investors truly care about.

In health, this problem is especially common because the market is complex and the feedback is noisy. Clinicians want one thing. Hospitals want another. Patients need something else. Payers ask different questions. Investors focus on fundability. Advisors suggest future use cases. Strategic partners talk about optionality. The founder tries to respond to all of it by building more.

But building more is not always the same as learning more.

And when a startup becomes overbuilt before it becomes understood, the product can start to work against the fundraising story.

Subscribe now

More products can hide less clarity

The first danger of an overbuilt startup is that more product can hide less clarity. A founder may have many features, but still not know the first buyer. They may have a broad platform, but still not know the first market. They may have a polished dashboard, but still not know which decision it improves. They may have multiple use cases, but still not know which one creates urgency. They may have a product that can do many things, but not enough evidence that any one thing is valuable enough to drive adoption.

This is where investors become cautious. A large product surface area can look impressive at first, but it can also raise questions about focus. Why has the company built so much before proving the core use case? Which part of the product is actually driving demand? Which feature creates measurable value? Which user depends on it? Which buyer cares enough to pay? Which workflow is painful enough to change? Which part of the product would customers miss if it disappeared tomorrow?

Founders often assume that a broader product makes the company look more mature. Sometimes it does, especially if the company has already proven demand and is expanding from a strong base. But at the early stage, breadth can create doubt. It can make investors wonder whether the founder is building because the market has pulled the company forward or because the company is still searching for what matters.

The difference is important. A startup that expands after proving a wedge is scaling from insight. A startup that expands before proving a wedge may be avoiding the hard work of focus.

Investors are not trying to punish founders for building. They are trying to understand what the product has proven. If the answer is unclear, more product does not solve the problem. It often makes the problem harder to see.

Founders often build to avoid learning

Building feels safer than learning because building is controllable. A founder can open the product roadmap, define a new feature, assign tasks, brief engineers, update designs, and show visible progress. Learning is more uncomfortable. It requires exposing the company to the market. It requires asking whether customers care, whether buyers will pay, whether the use case is urgent, whether the workflow fits, whether the product removes enough pain, and whether the company is solving something that matters now.

Many founders do not avoid learning consciously. They genuinely believe they are improving the company. But product work can become a refuge from commercial truth. It is easier to build another module than to hear that the buyer is unclear. It is easier to improve the dashboard than to test whether anyone will pay for it. It is easier to add AI than to prove the workflow problem. It is easier to expand the platform than to choose a narrow use case and accept that the rest can wait.

This is especially true in health because customer discovery can be slow and ambiguous. A clinician may like the product but not be the buyer. A hospital may explore a pilot but not have a budget. A pharma team may say the platform is interesting but not have a defined use case. A patient group may validate the need but not the business model. These signals create uncertainty, and building can make the founder feel like they are still moving forward while the market remains unresolved.

Investors notice when product development is being used as a substitute for market clarity. They hear it when the founder talks in features instead of evidence. They see it when the roadmap is more detailed than the customer strategy. They feel it when the demo is impressive, but the adoption path is vague. They become concerned when the company has built a lot but still cannot answer the basic questions of who needs it most, why they need it now, and what they will do differently because it exists.

The best founders do not build to avoid learning. They build to test what they have learned.

The platform temptation

The word platform is one of the most dangerous words in early-stage health fundraising. It can be powerful when it is earned, but dangerous when it arrives too early. Founders like platforms because they suggest scale, optionality, and ambition. A platform can serve multiple use cases, multiple stakeholders, multiple conditions, multiple markets, and multiple revenue streams. It makes the company sound bigger than a point solution.

The problem is that investors often hear platform and immediately ask what has been proven first.

A platform without a wedge is hard to fund because the investor does not know what to believe. Is the company a clinical workflow tool, a diagnostic engine, a data infrastructure company, a patient engagement product, a provider solution, a pharma partnership platform, an AI decision support system, or a services-enabled technology business? The founder may believe the answer is all of the above, but early investors usually need the answer to be much sharper.

This does not mean platform ambition is wrong. Some of the most valuable health companies become platforms over time. But they rarely start by asking the market to believe the full platform at once. They begin with a painful use case, a specific user, a clear buyer, a narrow workflow, a defined evidence path, or a focused commercial wedge. Once that wedge works, the platform becomes more credible because it is expanding from proof rather than possibility.

A platform should be the result of repeated value, not a way to avoid choosing where value begins.

This is where founders need discipline. They can still explain the long-term platform vision, but the fundraising story needs to make the first wedge obvious. Investors should understand what the company is proving now, why that first use case matters, and how it creates the right to expand later.

Without that sequence, the platform story can feel like a product trying to be everything before it has proven anything.

Share

Feature requests are not strategy

Another reason startups become overbuilt is that founders confuse feature requests with market strategy. This is common in health because every stakeholder sees the product through their own workflow, incentives, and frustrations. A clinician asks for a different view. A hospital contact asks for another integration. An advisor suggests an additional use case. A pilot customer wants a specific reporting layer. A strategic partner asks whether the product could also support something adjacent.

Some of these requests may be valuable. Some may reveal real adoption barriers. Some may point toward a stronger wedge. But many are simply context-specific preferences. They reflect one user, one institution, one workflow, one stakeholder, or one hypothetical future customer. If the founder treats every request as strategic, the product becomes a collection of other people’s opinions.

That is dangerous because every feature has a cost. It adds engineering time, design complexity, implementation burden, support requirements, onboarding friction, and narrative complexity. It also makes the company harder to explain. The more the product tries to do, the harder it becomes to identify what is essential.

Investors are not impressed by a roadmap that responds to every external suggestion. They want to see that the founder can separate signal from noise. A feature request should not automatically become product direction. The founder needs to ask what the request proves. Is this a one-off preference or a repeated pattern? Does it reduce adoption friction or add complexity? Does it strengthen the first wedge or distract from it? Does the buyer care? Does it support the next milestone? Would the customer pay more because of it? Would the product fail without it?

The strongest founders do not ignore customers, clinicians, advisors, or partners. They listen carefully. But they do not let every voice shape the product equally. They understand that product discipline is part of company discipline.

Overbuilding can weaken the fundraising story

A fundraising story needs to be clear enough for investors to carry. This is not only about the deck. It is about whether the investor can explain the company to partners, advisors, investment committees, co-investors, and future stakeholders. An overbuilt product often makes that harder.

When a company has too many modules, markets, use cases, and claims, the investor has to work harder to understand the core business. They may like parts of the product but still struggle to know what the company really is. They may see interesting technology but not a clean wedge. They may respect the founder’s work but worry that the business has not yet found focus.

This matters because investors are not just funding effort. They are funding a path to value. More product does not automatically make that path clearer. In fact, it can blur the path if the product has expanded faster than the evidence.

A founder may say the company serves hospitals, patients, payers, pharma, providers, and researchers. That might sound large, but it also suggests multiple buyers, multiple sales motions, multiple evidence requirements, multiple pricing models, and multiple adoption pathways. A founder may say the product combines AI, workflow software, analytics, patient engagement, clinical decision support, and services. That might sound sophisticated, but investors will ask which part drives the business.

The risk is that the company starts to look like a solution searching for its market rather than a company built around a clear market need.

The best fundraising stories usually have a strong centre. The investor understands the problem, the first customer, the wedge, the evidence, the milestone, and the reason capital matters now. The product can be ambitious, but the story has to be focused.

Subscribe now

The smallest valuable wedge

The alternative to overbuilding is not underbuilding. It is finding the smallest valuable wedge. This is the narrow part of the product and market where the company can prove something meaningful. It is not necessarily the smallest feature, and it is not necessarily the smallest market. It is the smallest focused use case that can demonstrate real value, reduce a real risk, and create a credible path to expansion.

For a health company, the smallest valuable wedge might be one clinical workflow, one patient population, one provider segment, one decision point, one diagnostic use case, one therapeutic indication, one administrative pain point, one buyer group, or one measurable outcome. The key is that the wedge must matter. It should not be narrow for the sake of being narrow. It should be narrow because focus creates proof.

A good wedge helps the founder answer important questions. Who has the pain? Why does it matter now? What does the product change? Who needs to use it? Who needs to approve it? What evidence proves it works? What would make the customer continue, expand, pay, or partner? What does success in this wedge unlock next?

This is what makes a company easier to fund. Investors can understand what the current round is designed to prove. They can see how capital turns into evidence. They can understand why the wedge matters and how it could lead to a broader platform over time.

A founder who says, “We are building a platform for the entire market,” asks investors to believe a lot at once. A founder who says, “This is the first wedge, this is why it matters, this is what we have learned, this is what the next round proves, and this is how it expands,” gives investors a sequence of belief.

That is the difference.

More products can create more implementation risk

In health, more product does not only create more internal complexity. It can also create more implementation risk for the customer. Every additional feature, workflow, integration, dashboard, data field, reporting layer, user type, and service component can make the product harder to adopt.

Founders often think more functionality makes the product more valuable. Buyers may see more work. A hospital may ask who will train staff, who will manage the integration, who will maintain the workflow, who will interpret the data, who will change behaviour, who will be responsible if the product is not used properly, and who will measure success. A product that looks powerful in a demo may feel heavy in a real operating environment.

This is why overbuilt products can struggle in healthcare. The product may solve several problems, but if it requires too much change, the customer may delay adoption. The company may believe it has created more value, while the buyer sees more operational burden.

Investors understand this. They know healthcare systems are already under pressure. They know staff are overloaded, budgets are constrained, and procurement is slow. They know that adoption depends not only on whether a product is useful, but whether the organisation can absorb it.

A focused product with a clear use case can sometimes be easier to adopt than a broad product with many capabilities. It creates less confusion, less training burden, less implementation friction, and clearer success criteria. That does not mean the company must remain narrow forever. It means the first adoption path should be as clean as possible.

In health, a product that is easier to adopt is often easier to fund.

Leave a comment

The product should prove the business

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most underrated skills in fundraising is confidence. Not the loud version of …

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Health companies are naturally complex. That is part of the sector. A founder may need to manage science, product, clinical validation, regulation, reimbursement, procurement, market access, patient safety, data protection, stakeholder incentives, behaviour change, and long sales cycles before the company can become truly investable. Investors understand this. They do not expect health companies to look like simple software businesses, and they do not expect every risk to be removed at the earliest stage.

But there is a difference between necessary complexity and unfundable complexity.

Necessary complexity is the reality of building in health. It is the set of risks that naturally comes with the category, the product, the science, or the market. Unfundable complexity is what happens when a founder stacks too many unresolved risks on top of each other and expects investors to believe they will all be solved at the same time.

This is one of the most common reasons health companies become hard to fund. The company may be exciting. The mission may be important. The science may be promising. The product may be useful. The market may be large. But when investors look at the business, they see too many things that need to become true before the company can work.

The founder is asking investors to believe in new science, a new workflow, a new buyer, a new reimbursement model, a new regulatory pathway, a new behaviour change, a new data infrastructure, a new category, and a new commercial motion, all at once. Individually, each risk may be manageable. Together, they can make the company almost impossible to underwrite.

This is the unfundable complexity problem. It is not that investors dislike ambition. It is that ambition becomes difficult to fund when the company depends on too many unproven assumptions becoming true in the right order.

Subscribe now

Investors are not afraid of risk

A common founder's misunderstanding is that investors avoid risk. They do not. Venture capital exists because investors take risks. The entire asset class is built around uncertainty, incomplete information, and the possibility that a company may become much more valuable if the right risks are reduced over time.

The issue is not the risk itself. The issue is risk concentration.

Investors can often underwrite one major risk if they understand it clearly. They may take scientific risks if the team is exceptional and the market is meaningful. They may take commercial risk if the technology is already strong. They may take regulatory risk if the pathway is credible and the value creation potential is large. They may take adoption risk if the economic case is compelling. They may take early market risk if the category is forming and the company has a credible wedge.

What becomes difficult is when the company carries many major risks at the same time without a clear plan for reducing them. If the science is unproven, the buyer is unclear, the payment model is uncertain, the workflow is disruptive, the regulatory pathway is unresolved, and the market category still needs to be created, the investor is not evaluating one risky company. They are evaluating a chain of dependencies.

Every link in that chain has to hold.

That is where investors slow down. They are not only asking whether the opportunity is big. They are asking how many assumptions need to work before the company becomes valuable. The more assumptions that need to work at the same time, the harder the company becomes to fund.

This is why founders need to understand how investors think about risk. They do not simply count upside. They map the route between today’s uncertainty and tomorrow’s value. If that route requires too many unresolved things to go right, the company can become unfundable even when the idea is strong.

Complexity becomes dangerous when it is not sequenced

Complexity is not always a problem. Some of the best health companies are complex. They involve difficult science, regulated markets, clinical evidence, long development timelines, and sophisticated stakeholder environments. Complexity can even be an advantage if it creates defensibility. A company that solves a difficult problem may be harder to copy, more valuable to strategic partners, and more meaningful to the healthcare system.

But complexity has to be sequenced.

Sequencing means the founder understands which risks need to be reduced first, which risks can wait, which risks are connected, and which milestones will make the company more fundable. Without sequencing, the company feels like a pile of open questions. With sequencing, the same company starts to feel more investable because investors can see the path.

This is where many founders lose investors. They describe all the things the company will eventually do, but they do not explain which risk comes first. They talk about the full platform, the broad market, the future reimbursement opportunity, the international expansion, the strategic partnerships, the clinical outcomes, the regulatory route, the enterprise sales motion, and the long-term vision. The company sounds ambitious, but not staged.

Investors need staging. They need to know what this round proves. They need to know which risk is being reduced now and why that risk matters more than the others. They need to know what the company will look like after the round, what evidence will exist, what uncertainty will remain, and why the next investor, customer, partner, or acquirer will care.

A complex company becomes more fundable when the founder can turn complexity into sequence. The question is not whether everything is solved today. The question is whether the founder knows what must be solved next.

Too many new things at once

The most dangerous version of the unfundable complexity problem appears when a company is trying to introduce too many new things into the market at the same time. A new technology is hard enough. A new workflow is hard enough. A new buyer is hard enough. A new reimbursement model is hard enough. A new regulatory pathway is hard enough. A new clinical behaviour is hard enough. A new market category is hard enough.

When a company combines several of these, the adoption burden becomes much heavier.

For example, a founder may have a promising AI tool that requires hospitals to change workflow, trust a new type of clinical decision support, integrate with existing systems, create a new budget line, accept a new risk profile, and measure outcomes in a way they do not currently measure. The product may be useful, but the number of changes required from the customer is high. Investors will ask whether the market is ready to absorb that much change.

Another founder may have a diagnostic platform that needs new evidence, new clinician behaviour, payer acceptance, reimbursement clarity, lab adoption, and a new understanding of where the test fits in the care pathway. Again, the company may be important, but investors will ask whether too many stakeholders need to change before the business can scale.

A therapeutic platform may face a different version of the same problem. The science may be novel, but the company may also need to prove a new modality, choose the right first indication, build a clinical development strategy, attract strategic interest, protect IP, recruit specialised talent, and raise enough capital to reach a meaningful inflection point. Each of those risks may be normal, but together they can create a high proof burden.

This is not about discouraging innovation. Healthcare needs new science, new tools, new models, and new categories. But founders need to understand that every new thing adds friction. The more new things the company asks the market to accept, the more evidence investors need before they believe.

Share

The market does not adopt complexity just because the problem matters

One of the most painful truths in health is that important problems do not automatically create fast adoption. A problem can be serious, expensive, frustrating, and widely recognised, and still remain unsolved for years. Healthcare systems are full of problems that everyone agrees are real. That does not mean they are easy to fix, easy to fund, or easy to sell into.

This is where founders sometimes misread the market. They assume that because the problem is obvious, the system will act. But healthcare systems do not adopt solutions simply because the problem matters. They adopt when the solution fits the incentives, workflow, budget, evidence requirements, procurement process, regulatory environment, and operational capacity of the organisation.

A founder may say the current system is broken. The investor may agree. But agreement that the system is broken is not the same as a belief that this company can change it. The investor still needs to understand who has the power to act, why they will act now, what evidence they need, how the product fits into existing behaviour, how the company gets paid, and what makes the adoption path realistic.

This is why complexity can make a company less fundable even when the mission is strong. The founder is often focused on the size of the problem. Investors are focused on the path through the system. A large problem with no clear adoption route may be less fundable than a smaller problem with a sharper path to proof.

The market does not reward founders for identifying complexity. It rewards founders who can navigate it.

Broad platforms often carry hidden complexity

Platform companies are especially vulnerable to the unfundable complexity problem. A platform can sound exciting because it suggests scale, optionality, and multiple routes to value. It may be able to support many indications, many workflows, many customer types, or many commercial models. For founders, this breadth feels like strength.

For investors, breadth can create concern if the first path is unclear.

A platform with too many possible applications can become hard to underwrite because investors do not know which proof point matters. If the company could serve hospitals, pharma, payers, researchers, employers, and patients, the founder may believe the market is large. But the investor hears multiple buyers, multiple sales motions, multiple evidence requirements, multiple budgets, and multiple adoption pathways.

That is not always strength. Sometimes it is confusion.

The strongest platform founders do not try to make investors believe everything at once. They choose a first path that proves something important about the platform. They explain why that path is the right starting point, what evidence it creates, why the market cares, and how it opens future opportunities. They make the platform feel staged rather than scattered.

This is important because optionality without sequence is not strategy. It is complexity. Investors may believe the platform could be valuable someday, but they still need to understand what the company is doing now. If the founder cannot explain the first wedge clearly, the platform can feel more like a research direction than an investable company.

Subscribe now

The proof burden rises with every assumption

Every health company has a proof burden. The proof burden is the level of evidence investors need before they believe the company can move forward. That burden depends on the category, the claim, the customer, the risk, and the stage of the company.

A company making a low-risk workflow improvement may need to prove usability, adoption, time savings, and budget relevance. A company making clinical outcome claims needs stronger evidence. A diagnostic company needs to show analytical and clinical relevance, and often a path to payment. A regulated device company needs to show safety, performance, regulatory logic, and adoption potential. A therapeutic company may need to generate deep scientific, preclinical, clinical, and strategic evidence over time.

The proof burden rises when the company adds more assumptions. If the founder is asking investors to believe in a new technology and a new buyer, the proof burden rises. If the company also requires a new workflow, the burden rises again. If the company depends on a new reimbursement model, it rises again. If the company is trying to create a new category, it rises again.

This is why founders should be careful with ambitious claims. Every claim creates a proof requirement. If the company claims better outcomes, investors will ask for evidence. If it claims cost savings, investors will ask who saves money and whether the savings are measurable. If it claims workflow efficiency, investors will ask whether the workflow has been tested. If it claims strategic value, investors will ask who would care and why.

A founder may think they are making the company more attractive by expanding the ambition. But if the ambition adds too many proof requirements, it can make the company harder to fund.

Focus is not a lack of ambition

Some founders resist focus because they worry it makes the company look smaller. They want investors to see the full vision. They want to show all the markets, all the use cases, all the future partnerships, all the possible products, and all the ways the company could grow. That instinct is understandable, especially when founders are trying to raise venture capital and need to show scale.

But focus is not the enemy of ambition. Focus is how ambition becomes fundable.

A focused company is not saying the future is small. It is saying the first path is clear. It is showing investors where the company begins, what it proves, and how that proof unlocks the next stage. It reduces the number of assumptions investors need to believe immediately and gives the company a more credible way to create value.

This is especially important in health because broad ambition without a narrow entry point can make the company look naive. Investors know that healthcare systems do not move easily. They know that adoption is slow, evidence matters, stakeholders are fragmented, and budgets are difficult. When a founder claims the company can transform a large part of the system without explaining the first narrow path, investors become cautious.

The strongest founders can show both ambition and discipline. They can explain the big vision, but they do not ask investors to fund the entire vision at once. They show the first risk to reduce, the first stakeholder to win, the first evidence to create, and the first value inflection to reach.

That is what makes complexity investable.

How to make complexity fundable

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most confusing parts of building a health company is that almost everyone has an opinion. Advisors have opinions. Clinicians have opinions. Professors have opinions. Investors have opinions. Operators have opinions. Consultants have opinions. Strategic partners have opinions. Mentors, accelerators, grant reviewers, hospital contacts, pharma scouts, regulatory experts, and fellow founders all have opinions.

At the beginning, this feels useful. The founder wants to learn, and the company is still forming. Every conversation seems to reveal something important. A clinician explains the workflow. A professor challenges the science. An investor questions the market. An operator points out a commercial risk. A consultant suggests a regulatory route. An advisor recommends a different use case. A hospital contact says the product needs another feature. Someone else says the company should focus on a completely different buyer.

The founder leaves each conversation with more information, but not always more clarity.

This is the expert feedback problem. Health founders are surrounded by smart people, but smart feedback does not automatically become a good strategy. In fact, too much expert feedback can make a company slower, more confused, and less decisive if the founder does not know which feedback actually matters.

The danger is not that experts are wrong. Many of them are genuinely helpful. The danger is that their advice is shaped by their own context, incentives, experience, risk tolerance, and view of the market. A clinician will usually see the company through the clinical workflow. A professor may see it through scientific validity. An investor may see it through fundability. A regulatory consultant may see it through compliance risk. A commercial operator may see it through selling difficulty. A strategic partner may see it through their own corporate priorities.

Each perspective can be useful. None of them is the whole truth.

The founder’s job is not to collect as much advice as possible. The founder’s job is to decide which advice should change the company.

Subscribe now

More feedback does not always create more clarity

There is a point where feedback stops helping and starts creating noise. Most founders do not notice this immediately because advice feels productive. The founder is taking meetings, learning from experienced people, validating assumptions, and building a network around the company. It can feel like progress, especially in health, where credibility matters and access to experts is often hard to earn.

But feedback can become a substitute for decision-making. Instead of choosing a first market, the founder keeps asking more people what they think. Instead of committing to a regulatory pathway, the founder keeps collecting opinions. Instead of testing pricing directly with buyers, the founder asks advisors whether the price feels reasonable. Instead of narrowing the use case, the founder adds more possibilities because each expert sees another opportunity.

This is how a company becomes heavier without becoming sharper.

The deck starts to change after every conversation. The product roadmap becomes crowded with features suggested by people who may never buy the product. The market narrative becomes broader because each expert sees a different application. The founder starts using phrases like “we have had very positive feedback from experts,” but struggles to explain what that feedback has actually proven.

Investors can feel this quickly. A founder who has absorbed too many opinions without filtering them often sounds less clear, not more clear. The company becomes difficult to understand because it is carrying the fingerprints of too many outside voices. The problem, customer, use case, evidence plan, regulatory logic, and commercial strategy all start to blur.

This is why more feedback does not always make a company more fundable. Fundability usually improves when the founder becomes clearer, not when the company becomes more crowded with perspectives.

Experts give advice from where they stand

One of the most important things founders need to understand is that expert feedback is never neutral. It may be thoughtful, experienced, and well-intentioned, but it still comes from a specific position. The expert is seeing the company through the lens of their own world.

A clinician may focus on whether the product fits real patient care, but they may not understand how the hospital will buy it. A professor may focus on scientific depth, but they may not understand what level of proof is needed for venture financing. A regulatory expert may focus on the safest pathway, but that path may not always match the company’s capital constraints. An investor may push for a sharper market narrative, but they may not fully understand the clinical complexity. A strategic partner may suggest a direction that is useful for their company, but not necessarily for the startup.

This does not mean the advice is bad. It means the founder has to interpret it properly.

The same piece of feedback can be valuable or dangerous depending on how it is used. If a clinician says the product needs a new feature, that may reveal a real workflow barrier. It may also reflect one institution’s preference. If an investor says the market is too narrow, that may mean the company needs to explain the expansion path better. It may also mean that the investor is not the right fit for the category. If a professor says the science needs more depth, that may be true for publication, but not necessarily for the next financing milestone.

Founders get into trouble when they treat all expert feedback as equally important. They start reacting to the status of the person giving the advice rather than the relevance of the advice itself. A well-known professor says something, so the company changes direction. A senior investor challenges the story, so the founder rewrites the whole narrative. A respected clinician asks for a feature, so it goes on the roadmap.

That is not a strategy. That is outsourcing judgment.

Advice can hide uncertainty

Sometimes founders keep collecting feedback because they are avoiding the discomfort of making a decision. This is common in health because decisions are expensive. Choosing the first indication, first use case, first customer segment, first product boundary, first evidence package, or first regulatory path can feel scary. Once the founder chooses, other possibilities must be delayed or ignored.

Expert feedback gives the founder permission to keep the decision open. There is always one more person to ask, one more advisor to consult, one more investor to speak with, one more clinician to interview, one more regulatory view to compare. The company appears to be learning, but in reality, it may be postponing commitment.

Investors are sensitive to this because venture-backed companies need decision-making discipline. They do not expect founders to know everything, but they do expect them to make hard choices with incomplete information. A founder who cannot filter advice may struggle when the company needs to move quickly, allocate capital, prioritise milestones, hire the right people, or say no to distracting opportunities.

This is where too much advice can make a founder less fundable. It can signal that the founder does not yet have the confidence or clarity to lead the company through uncertainty. The founder may be surrounded by impressive advisors, but if every external opinion changes the company’s direction, investors will worry that the business has no internal centre of gravity.

The strongest founders listen widely but decide narrowly. They gather input, understand the pattern, separate signal from noise, and then make a clear choice. They do not need every expert to agree before they act. They need enough evidence to move forward intelligently.

Subscribe now

The advisor problem

Health startups often build advisory boards early because credibility matters. A strong advisory board can help a company access clinical insight, regulatory understanding, scientific validation, market knowledge, investor confidence, and strategic relationships. Good advisors can save founders from expensive mistakes.

But advisory boards can also become a hiding place.

Some founders use advisors to signal credibility before the company has enough evidence. The deck becomes full of impressive names, but the business itself is still unclear. Other founders confuse having advisors with having execution capability. They assume that because the company has access to senior experts, it has solved the knowledge gap. Investors know the difference.

An advisor is not a strategy. An advisor is not a buyer. An advisor is not a management team. An advisor is not proof that the company can execute.

The real question is what the advisor actually changes. Are they helping the company make better decisions? Are they opening the right doors? Are they pressure-testing the evidence plan? Are they helping the founder understand the market? Are they reducing a real risk? Are they engaged enough to matter, or are they mostly a name on a slide?

Founders should be honest about this. A small number of deeply useful advisors is often more valuable than a long list of impressive but passive names. Investors care less about how many experts are attached to the company and more about whether the founder knows how to use expertise properly.

The best advisors make the company sharper. Weak advisory structures make the company look decorated, but not stronger.

The danger of building by committee

The expert feedback problem becomes most damaging when the company starts building by committee. This happens when the product, market, evidence plan, and narrative are shaped by too many external opinions without a clear founder-led strategy holding them together.

The product becomes a collection of requests. The pitch becomes a collection of investor comments. The clinical plan becomes a collection of advisor preferences. The market strategy becomes a collection of possible use cases. The result is a company that tries to satisfy everyone and ends up convincing no one.

This is especially dangerous in health because complexity is already high. A health company may already need to manage scientific risk, regulatory risk, clinical risk, reimbursement risk, data risk, adoption risk, and financing risk. If the founder adds too many competing opinions on top of that complexity, the company becomes harder to understand and harder to fund.

Investors do not want a company that has been shaped by consensus from every expert who has touched it. They want a founder who can explain why the company is making the choices it is making. They want to hear the logic behind the first market, the product scope, the evidence plan, the regulatory approach, the hiring sequence, and the financing milestone. They want to know that the founder is listening, but also leading.

This distinction is important. Being coachable does not mean being directionless. Listening to feedback does not mean changing the company after every conversation. A founder can be humble and decisive at the same time. In fact, that combination is often what investors are looking for.

Share

How to filter expert feedback

The best founders do not ask whether feedback is smart. They ask whether it is relevant to the decision in front of them. This is a different question. Smart people can give advice that is not useful for the current stage of the company. An expert may be right in general, but wrong for the milestone the company is trying to reach now.

The founder should first ask what type of decision the feedback relates to. Is it about clinical workflow, scientific validity, market demand, regulatory pathway, reimbursement, pricing, product usability, fundraising narrative, or strategic positioning? Once the founder understands the category, they can decide whether the person giving the feedback has the right context to influence that decision.

The founder should also ask whether the feedback is a pattern or an isolated opinion. If one clinician asks for a feature, that may be interesting. If ten clinicians across different institutions identify the same workflow barrier, that is more important. If one investor dislikes the market, that may reflect fund fit. If multiple relevant investors struggle with the same part of the story, the founder should pay attention. If one advisor suggests a new application, that may be optionality. If several market participants point to the same urgent use case, that may be a strategy.

Context matters. Pattern matters. Relevance matters.

The founder also needs to separate feedback that improves the company from feedback that merely expands the company. Some advice creates focus. Some advice creates more work. Some advice reduces risk. Some advice adds complexity. Some advice makes the investment story clearer. Some advice makes the company sound bigger but harder to underwrite.

The strongest founders are disciplined about this. They do not accept advice just because it sounds intelligent. They ask whether it helps the company become more focused, more credible, more fundable, or more valuable.

When feedback becomes a fundraising risk

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and Emerging Managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Every founder has a part of the business they would rather not look at too closely. It is rarely because they are lazy or careless. More often, it is because that part of the company feels uncomfortable, uncertain, or outside the founder’s natural strength. For one founder, it is sales. For another, it is a regulatory strategy. For another, it is pricing, evidence generation, reimbursement, governance, hiring, market access, financial discipline, or the uncomfortable question of whether the company is focused enough.

This is the founder's blind spot. It is the risk that sits in the company long before the founder is ready to admit it. The founder can feel it, but they avoid giving it language. They work around it. They talk past it. They spend more time on the parts of the company where they feel strong and less time on the parts that keep creating tension.

The problem is that investors usually notice the blind spot very quickly. They may not see everything about the company in the first meeting, but they are trained to look for the gap between the story and the business. They listen to what the founder explains clearly and what they explain vaguely. They notice which risks are handled directly and which risks are softened, delayed, or avoided. They pay attention to the questions that make the founder more defensive, less precise, or more general.

This matters because fundraising is not only a test of ambition. It is a test of self-awareness. Investors do not expect early-stage companies to be perfect. They know there will be gaps, risks, unknowns, and open questions. What they want to know is whether the founder sees the company clearly enough to work through those risks in the right order. A founder who can name the weakness and explain how they are addressing it is much easier to trust than a founder who keeps pretending the weakness is not there.

The risk you avoid is often the risk investors notice first.

Subscribe now

Why founders avoid the hard part

Founders avoid different parts of the business for different reasons. Some avoid sales because they come from a technical, scientific, clinical, or product background, and selling feels uncomfortable. Some avoid regulatory strategy because it feels slow, expensive, and complex. Some avoid pricing because they do not want to hear that customers may not pay what the model assumes. Some avoid evidence generation because the truth may be that the company needs more proof before institutional capital will take it seriously.

In health, this avoidance is especially common because the company often contains many types of risk at once. A health founder may need to understand product, science, clinical evidence, regulation, reimbursement, procurement, market access, data protection, patient safety, stakeholder incentives, and venture financing. Very few founders are naturally strong across all of those areas. Most are excellent in one or two and much weaker in others.

That is not the problem. No founder is complete at the beginning. The problem begins when the founder does not recognise where the company is exposed. They may keep improving the deck while avoiding buyer discovery. They may keep adding product features while avoiding pricing conversations. They may keep talking about clinical value while avoiding reimbursement. They may keep raising the market size while avoiding the first narrow use case. They may keep discussing future partnerships while avoiding the fact that the current milestone does not create enough value.

Avoidance often disguises itself as progress. The founder is busy, but not addressing the hardest question. The company is moving, but not necessarily becoming less risky. The team is producing materials, building products, joining programmes, taking meetings, and updating investors, but the blind spot remains untouched. From the inside, this can feel like momentum. From the outside, investors can often see that the company is circling around the real issue.

This is why blind spots are so dangerous. They do not always stop a company immediately. They quietly shape the company’s decisions until the risk becomes too large to ignore.

The blind spot often hides inside the founder’s strength

The most difficult blind spots are not always the obvious weaknesses. Sometimes they are hidden inside the founder’s strongest area. A scientific founder may be so confident in the technology that they underinvest in market focus. A product founder may keep building because product progress feels more controllable than commercial validation. A clinical founder may rely too heavily on clinical need and underestimate buying complexity. A commercial founder may sell the vision well but underestimate the evidence burden required in health.

This is where investors become careful. They know that a founder’s strength can become a distortion if it dominates the entire company. The scientist may believe better data will solve every concern. The product builder may believe that more features will create adoption. The clinician may believe an obvious need will translate into demand. The salesperson may believe that narrative can outrun proof. Each of these strengths is valuable, but none of them can carry the company alone.

A founder’s background shapes what they notice first. It also shapes what they miss. That is why self-awareness matters so much. The strongest founders understand their own bias. They know what they are naturally drawn toward, and they know what they are likely to avoid. They can say, “This is where I am strong, and this is where the company needs support.” That level of honesty creates confidence because it shows the founder is not confusing personal expertise with company readiness.

Investors do not need the founder to be perfect. They need the founder to be coachable, precise, and honest about the company’s real risks. A founder who understands their blind spot can hire around it, advise around it, test it, and bring it into the operating plan. A founder who ignores it often lets it become the reason the round stalls.

Share

Investors listen for what is missing

During fundraising, founders often focus on what they want to say. Investors are listening for what is missing. This is one of the reasons blind spots become visible quickly. The founder may have a polished answer on the market, the product, the team, and the vision, but when the conversation moves toward the uncomfortable area, the answer becomes less clear.

If sales is the blind spot, the founder may talk about market need but struggle to explain the buyer, budget, urgency, sales cycle, or conversion path. If regulatory is the blind spot, they may talk about future approval but remain vague on classification, evidence requirements, timeline, cost, and decision points. If pricing is the blind spot, they may talk about value but avoid specific willingness-to-pay evidence. If financial discipline is the blind spot, they may talk about ambition but struggle to explain burn, runway, hiring sequence, or milestone-based capital use.

Investors notice these shifts. They notice when the founder becomes more abstract. They notice when answers become longer but less specific. They notice when the founder keeps returning to the same comfortable part of the story instead of answering the question directly. They notice when a key risk is described as something to figure out later, even though it should already be part of the strategy.

This does not mean every unknown is fatal. Early-stage companies are built around unknowns. But there is a difference between an unknown that is understood and an unknown that is being avoided. Investors can usually feel the difference. An understood risk has language around it. It has a plan. It has sequencing. It has a reason why it is not yet solved and a path for how it will be tested. An avoided risk stays vague.

The founder may think they are protecting the company by not drawing attention to the weakness. In reality, they may be making the weakness louder.

The blind spot becomes a diligence problem

A blind spot may not kill the first meeting, but it often becomes a problem in diligence. This is where the founder’s story gets tested against the company’s materials, conversations, model, evidence, and operating reality. If the blind spot has been avoided, diligence will usually expose it.

If sales is the blind spot, the investor will find that the pipeline is active but not qualified, the pilots have no conversion path, the buyer is unclear, and the revenue assumptions are not supported by real customer evidence. If regulatory is the blind spot, the investor will find that the pathway is more assumed than understood. If pricing is the blind spot, the model will depend on a price point that has not been tested. If governance is the blind spot, the data room may reveal messy ownership, weak documentation, unclear decision rights, or founder agreements that create future risk.

This is why blind spots damage momentum. The investor may like the company, but the diligence process starts to reveal that one part of the business is less developed than the pitch suggested. The round slows down because the investor has to decide whether the gap is normal early-stage risk or a sign that the founder does not understand the business deeply enough.

That distinction matters. Investors can invest through risk, but they are less comfortable investing through denial. Risk can be priced, staged, structured, diligenced, and managed. Denial is harder. If the founder does not see the problem, the investor has to worry that the company will keep making decisions around the problem rather than through it.

This is why founders should not wait for diligence to reveal the blind spot. They should identify it before the investor does and explain how they are working through it. That does not weaken the company. It often strengthens trust.

The blind spot changes by stage

Founder blind spots also change as the company matures. At the earliest stage, the blind spot may be market clarity. The founder has a technology, product, or scientific insight, but does not yet know the first customer, first use case, first buyer, or first proof point. At seed, the blind spot may be evidence quality. The company has interest, a prototype, early conversations, or pilot activity, but not enough proof that the product can create repeatable value. At Series A, the blind spot may be scalability. The company has early evidence, but investors want to understand whether the business can move beyond founder-led selling, one-off pilots, bespoke implementations, or narrow relationships.

This matters because some founders keep solving yesterday’s problem. They continue proving what investors already believe while avoiding the next risk that matters. A founder may keep improving the product when the real question has become distribution. A founder may keep collecting clinical feedback when the real question has become budget ownership. A founder may keep strengthening the science when the real question has become development sequencing. A founder may keep adding advisors when the real question has become execution capability.

The best founders understand that each financing stage requires a new level of honesty. What made the company credible at pre-seed may not be enough at seed. What helped the company raise seed may not be enough for Series A. The investor is always asking what risk needs to be reduced next. If the founder is still focused on the risk they already know how to solve, the company can start to look stuck.

This is one of the reasons fundraising is useful even when it is painful. It forces the company to confront the risks that the market sees, not only the risks the founder prefers to work on.

Leave a comment

The cost of not naming the problem

The cost of avoiding the blind spot is not only investor rejection. It also affects how the company operates. When the founder does not name the problem, the team cannot organise around it properly. Hiring becomes reactive. Advisors are chosen for reputation rather than gap-filling. Product decisions drift. Sales activity becomes noisy. Financial planning becomes disconnected from milestones. The company keeps moving, but it does not build enough discipline around the part of the business that most needs attention.

This is especially damaging in health because delays are expensive. A year spent avoiding the wrong question can cost the company more than money. It can cost evidence, momentum, credibility, market position, and future financing options. A company that avoids reimbursement for too long may build a product with no payment path. A company that avoids a regulatory strategy may generate data that does not support the right pathway. A company that avoids pricing may discover too late that willingness to pay is weaker than expected. A company that avoids governance may create legal or ownership issues that become difficult to clean up later.

Naming the problem early gives the company more options. It allows the founder to design experiments, hire the right people, ask better questions, and use capital more intelligently. It also changes the tone of investor conversations. Instead of appearing unaware, the founder appears disciplined. Instead of waiting to be challenged, the founder shows that they already understand where the company is exposed.

That is a different signal.

It tells investors the founder is not just selling the company. They are building it with clear eyes.

P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Subscribe now and operate like a pro.

How to find the risk you are avoiding

The hardest part of a blind spot is that it rarely feels like a blind spot from the inside. It feels like something that can wait. It feels like something that will become easier after the next hire, the next pilot, the next investor call, the next product release, or the next round. Founders are good at rationalising delay because delay often feels safer than confronting a difficult truth before the company has enough resources to solve it.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the hardest transitions in health is the move from science to company. A discovery can be impressive. A mechanism can be novel. A platform can be technically strong. A patent can be defensible. A dataset can be valuable. A clinical insight can be meaningful. But none of those things automatically make the company investable.

This is where many health founders get caught. They believe the strength of the science should be enough to carry the fundraising story. They assume that if the technology is differentiated, if the research is credible, if the unmet need is obvious, and if the clinical potential is large, investors should understand why the company deserves capital. But investors are not only evaluating whether the science is interesting. They are evaluating whether the science can become a business.

That distinction matters because venture capital does not fund discovery alone. It funds the possibility that discovery can be turned into value. That means investors are asking a different set of questions. They want to know what the company is building, which market it is entering first, what evidence is needed, which risks need to be reduced, who the buyer or acquirer could be, what milestones increase value, and whether the team can move the asset from technical promise to commercial opportunity.

The science may be the reason the company exists, but it is not the whole investment case. A founder still needs to explain why this should become a company, why now is the right time, why this team can execute, why the first market makes sense, why the next milestone matters, and why capital will make the business more valuable.

This is the science-to-company gap. It is the space between having something technically or clinically promising and having something that investors can underwrite as a company.

Subscribe now

Strong science can still be an unclear company

One of the most common mistakes scientific founders make is assuming that technical strength creates commercial clarity. It does not. A company can have strong science and still be difficult to understand as an investment. The problem is not that the science is weak. The problem is that the business around the science has not yet been shaped clearly enough.

This happens often with university spinouts, platform technologies, diagnostics, medtech, computational biology, AI health tools, therapeutics, and research-led companies. The founder can explain the mechanism, the technical breakthrough, the data, the discovery process, or the clinical rationale, but struggles to explain the company in business terms. The pitch becomes heavy on what has been built and light on what will be proven next. The investor hears an impressive technical story, but not yet a clear investment story.

A scientific breakthrough may create many possible directions. It could support multiple indications, multiple customer types, multiple business models, multiple applications, or multiple partnership routes. From the founder’s perspective, this optionality can feel like strength. It shows that the technology is broad and powerful. From the investor’s perspective, too much optionality can feel like lack of focus. If everything is possible, it becomes harder to understand what the company is actually going to do first.

This is why investors often push founders toward sharper choices. They want to know the first use case, the first market, the first proof point, the first development path, and the first value inflection. They are not asking because they lack imagination. They are asking because companies do not become investable through theoretical optionality. They become investable when the founder can show how the first path creates evidence, value, and momentum.

Great science opens doors. Strategy decides which door to walk through first.

Investors need a company, not only an invention

An invention can be valuable, but a venture-backed company needs more than an invention. It needs a path. That path may be scientific, clinical, regulatory, commercial, strategic, or transactional, depending on the category. But it has to be visible enough for investors to believe that capital can move the company forward.

This is where some founders misunderstand the role of the investor. They think investors are there to appreciate the technical promise. In reality, investors are trying to understand whether the next round of capital can turn that promise into a more valuable asset. That requires more than a good idea or a strong patent. It requires a clear view of what the money will prove.

If the company is raising pre-seed or seed capital, the investor may not expect clinical proof or commercial revenue. But they will still want to know what the round is designed to de-risk. Is it proving technical feasibility? Is it generating early validation data? Is it clarifying the regulatory path? Is it narrowing the first indication? Is it building the right team? Is it creating a data package that could attract strategic interest or a stronger institutional round?

At Series A, the expectations become different. The investor may want to see stronger evidence, clearer milestones, more disciplined market selection, a credible development plan, and a more mature understanding of risk. The company does not need to have everything solved, but it needs to show that it is moving from research logic to company logic.

This is why the phrase “we have great science” is never enough. The investor needs to understand how the science becomes a company. They need to understand what the first product, asset, indication, customer, partner, or value inflection looks like. They need to see how the company moves from potential to proof.

The first market matters more than the total market

Founders often try to make the company look bigger by showing how many markets the science could serve. They explain that the platform could apply to multiple diseases, multiple workflows, multiple patient groups, multiple hospital departments, or multiple strategic partners. This may be true, but it can weaken the pitch if the founder cannot explain the first market clearly.

Investors do not only want to know how large the total opportunity could become. They want to know how the company enters the market. The first market is where the company learns, proves, focuses, and builds credibility. If the first market is poorly chosen, the company can spend years generating activity without creating a clear value inflection.

The first market should not be chosen only because it is large. It should be chosen because it gives the company the best chance to prove something that matters. For a therapeutic company, this may mean choosing an indication where biology, clinical development, unmet need, competitive dynamics, and strategic interest align. For a diagnostic company, it may mean choosing a use case where the test changes a decision and has a credible payment pathway. For a medtech company, it may mean choosing a workflow where the product solves a real problem without creating excessive adoption friction. For a platform company, it may mean choosing a focused application that proves the platform’s value without forcing investors to believe everything at once.

This is where many research-led founders struggle. They want the company to be understood through the full breadth of the science. Investors often want the company to be understood through the first investable path. Breadth may matter later, but focus matters first.

A company that can explain its first market clearly is easier to fund because investors can understand what progress looks like. They can see what evidence needs to be generated, what risks remain, who cares if it works, and why the next milestone changes the value of the business.

Optionality is useful only when the first path is credible

Optionality is one of the most overused ideas in early health pitches. Founders often say the platform can be used across many applications, diseases, customers, or partners. They believe this makes the company more attractive because it shows scale. Sometimes it does. But optionality only creates value when investors believe the company has a credible first path.

Without a clear first path, optionality can look like avoidance. It can feel like the founder has not made the difficult strategic choices yet. It can suggest that the company is trying to keep every door open because it does not know which one matters most. In science-led companies, this can become especially dangerous because the technical possibility is often much wider than commercial reality.

A platform may be able to do many things, but the company cannot prove all of them at once. A technology may have many theoretical applications, but the team cannot pursue every market, regulatory path, partnership model, and evidence package simultaneously. A founder may want to show ambition, but investors need to see sequencing.

Sequencing is what turns optionality into strategy. The founder needs to explain what comes first, what comes later, and why. They need to show why the first path is the right one, what it proves, how it creates value, and how it opens the next path. If the first path works, optionality becomes more credible. If the first path is vague, optionality becomes noise.

This is a critical difference. Investors are not against big visions. They are against unfocused visions. The best founders can hold both ideas at the same time. They can show the ambition of the platform while still being precise about the first evidence path.

The team has to change as the company changes

The science-to-company gap is not only about strategy. It is also about team evolution. A research project can be led by scientific excellence alone. A company cannot. As the company moves forward, it needs commercial judgment, regulatory understanding, clinical development experience, product discipline, operational structure, financial planning, and fundraising capability.

This does not mean scientific founders need to become experts in everything. It means they need to understand what the company is missing and bring in the right people at the right time. Investors do not expect early teams to be complete, but they do look for self-awareness. They want to know whether the founder understands the gap between where the company is today and what it will need to become.

A brilliant scientific founder can lose investor confidence if they cannot explain how the company will develop beyond the lab. The investor may believe in the technology, but worry about execution. They may ask who will lead clinical development, who understands regulatory strategy, who can build partnerships, who can manage a financing process, who can translate the science into a business case, and who has built something like this before.

This is especially important for academic spinouts. The academic environment rewards discovery, publication, technical depth, and scientific credibility. The company environment rewards focus, execution, milestone discipline, capital efficiency, and decision-making under uncertainty. Those worlds overlap, but they are not the same. A founder moving from one to the other needs to show they understand the shift.

The strongest founders are not defensive about this. They do not pretend that the science team already has every capability. They explain where the team is strong, where it needs to be strengthened, and what the next hires or advisors will unlock. That kind of honesty builds trust because it shows the founder is thinking like a company builder, not only a researcher.

The milestone has to create company value

A common weakness in science-led fundraising is that the use of funds is described as a list of activities instead of a value creation plan. The founder says the round will fund experiments, development, hiring, regulatory work, product build, clinical preparation, or market exploration. These may all be necessary, but investors need to understand why they matter.

Capital should not just pay for work. It should create value. That means the founder needs to explain what the company will know, prove, unlock, or de-risk after the round. If the company raises capital and spends it, what changes? Does the data package become stronger? Does the regulatory path become clearer? Does the first market become validated? Does the product become ready for clinical use? Does the company become attractive to strategic partners? Does the next financing become easier because a key risk has been reduced?

This is one of the most important shifts from science thinking to company thinking. In science, the next experiment may be valuable because it advances understanding. In venture, the next milestone must also advance the company. It needs to make the asset more fundable, more partnerable, more defensible, more credible, or more valuable.

Founders should be able to explain the value of each major milestone in investor language. Not just what they will do, but why it changes the risk profile of the company. Not just what data they will generate, but who will care about that data. Not just what development work will be completed, but how that work supports the next financing, partnership, regulatory step, or commercial pathway.

This is where many technically strong companies become weak fundraising stories. They know what they want to work on, but they do not explain why that work creates investable progress.

Leave a comment

The company must become easier to believe

The real job of the founder is to make the company easier to believe over time. That does not mean oversimplifying the science or pretending the risks are lower than they are. It means organising complexity so investors can understand what matters.

Health companies are naturally complex. There may be biology, engineering, clinical evidence, regulatory pathways, reimbursement questions, market access issues, manufacturing requirements, product adoption risks, data quality concerns, IP questions, and strategic partnership possibilities. The founder cannot remove all complexity, but they can structure it.

A founder who explains the company clearly creates confidence. They show investors where the science is strong, where the company is still early, what needs to be proven next, which risks matter most, and why the first path is credible. A founder who hides inside technical detail creates the opposite effect. The investor may respect the science but still feel unsure about the company.

This is one reason clarity matters so much in fundraising. Clarity is not a marketing trick. It is a signal of judgment. If the founder can explain a complex company simply without making it shallow, investors start to believe the founder understands the business deeply. If the founder cannot explain the company without drifting into technical detail, investors may worry that the company is not yet strategically formed.

The best health founders do not make investors do all the translation. They do not assume the science will speak for itself. They translate the science into a company narrative that can survive partner meetings, diligence, investment committees, strategic conversations, and future financing rounds.

What investors are really underwriting

Investors are not underwriting science in isolation. They are underwriting the path from science to value. That path is different depending on the company, but the underlying question is similar: can this team turn this technical or clinical insight into something that becomes significantly more valuable with capital?

That is why the investment case needs to connect the science, the team, the market, the evidence, the milestones, and the financing strategy. If one of those pieces is missing, the company becomes harder to fund. Strong science with no market focus is hard to underwrite. Strong science with no team evolution is hard to underwrite. Strong science with no milestone logic is hard to underwrite. Strong science with no credible first path is hard to underwrite.

This does not mean every early company needs to have all the answers. Investors know that early health companies are built through uncertainty. But they need to believe the founder knows how to move through that uncertainty in the right order. They need to see that the founder is not only asking for capital to continue the research, but to build the company.

That is the difference.

Research asks what is true.

A company asks what can be built, funded, adopted, defended, scaled, partnered, or acquired from what is true.

Both matter. But they are not the same.

P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Share

The real transition from science to company

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most common traps in healthtech fundraising is mistaking a clinical champion …

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most dangerous moments in fundraising is when a founder starts to believe the…

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Most founders think the data room is something they prepare after an investor asks for it. They treat it like an administrative step in the fundraising process. A folder gets created, documents get uploaded, the pitch deck goes in, the cap table goes in, the financial model goes in, a few contracts go in, and the founder assumes the investor now has what they need.

But that is not how diligence works.

A data room is not the diligence. It is only the place where diligence begins. The real diligence happens when an investor tries to understand whether your company is as strong, as credible, and as investable as it sounded during the first conversation.

That is where many founders lose momentum. Not because the investor suddenly stopped liking the company. Not because the opportunity disappeared. But because the materials inside the data room do not help the investor build conviction.

This is one of the most misunderstood parts of fundraising.

Founders often believe that diligence is about providing information. Investors are actually trying to build belief. They are trying to understand whether the story holds together when it is placed under pressure. They are checking whether the claims in the pitch deck are supported by evidence. They are testing whether the founder understands the real risks. They are looking for consistency between the narrative, the documents, the financial model, the team, the market, the regulatory pathway, and the next milestone.

The data room is not just a folder.

It is where the investor starts to decide whether the company is real.

Subscribe now

The mistake founders make with data rooms

The most common mistake is treating the data room like a warehouse.

The founder collects everything they can find, uploads it into folders, gives the investor access, and assumes the job is done. There may be a deck, a model, incorporation documents, customer notes, IP documents, clinical materials, market research, contracts, and a few spreadsheets. Technically, the files exist. But the data room does not explain the company.

This creates a problem because investors are not only reviewing documents. They are trying to understand the logic of the investment.

A weak data room forces the investor to do too much work. They have to connect the pitch to the evidence. They have to guess which documents matter most. They have to interpret technical material without enough context. They have to understand whether traction is meaningful or superficial. They have to work out whether the regulatory pathway is clear or just assumed. They have to decide whether the next financing milestone is a real value inflection point or simply a list of expenses.

When the data room is messy, investors do not usually say, “This founder is busy.” They start to wonder whether the founder is ready.

That matters.

Fundraising is not only about whether the investor likes the company. It is about whether the investor feels confident enough to keep moving the company through their own process. A founder may have a strong first call and still lose momentum during diligence because the materials do not support the level of conviction needed to move forward.

This is especially true in health.

Health companies are rarely simple. There may be clinical risk, regulatory risk, reimbursement risk, scientific risk, adoption risk, procurement risk, implementation risk, and financing risk. The investor is not only asking whether the company is exciting. They are asking whether the team can manage complexity.

The data room gives them an early answer.

The data room should protect momentum

A good first investor call creates interest. A good second call can create excitement. But diligence is where excitement either becomes conviction or starts to fade.

This is why the data room matters so much.

The founder’s job is not to impress the investor with the number of files uploaded. The job is to protect the momentum that has already been created. Every document should help the investor understand something important. Every section should answer a question the investor is likely to ask. Every folder should make the company easier to evaluate, not harder.

If the founder says there is strong market pull, the data room should show evidence of market pull. Not just friendly emails or vague interest, but proof that the problem is painful enough for customers, clinicians, payers, hospitals, pharma partners, or other stakeholders to act.

If the founder says the science is differentiated, the data room should make that differentiation clear. Not by burying investors inside technical documents, but by helping them understand what has been proven, what remains uncertain, and why the next study or development milestone matters.

If the founder says the regulatory pathway is clear, the data room should explain the pathway. It should show the assumptions, classification, timeline, cost, risks, decision points, and the evidence needed to move through the next stage.

If the founder says this round will create value, the model and use of funds should prove it. The investor should be able to see how the money raised turns into evidence, milestones, and a stronger position for the next round.

This is where many founders fail.

They pitch one version of the company and then show a weaker version inside the data room. The story sounds strong on the call, but the documents do not carry the same strength. The deck says one thing. The model suggests another. The clinical plan is unclear. The commercial evidence is thin. The cap table creates questions. The use of funds looks like spending, not value creation.

The investor does not need everything to be perfect. Early-stage companies are not perfect. But they do need the founder to be clear.

Clarity creates trust.

Confusion creates doubt.

Investors read for patterns

Founders often assume investors read a data room like a checklist.

They do not.

Investors read for patterns.

They are looking for consistency. They want to see whether the company described in the pitch deck is the same company shown in the documents. They want to see whether the founder is precise or vague. They want to see whether the risks are openly understood or quietly avoided. They want to see whether the company has evidence or just ambition.

This is why a data room can change how an investor feels about the founder.

A clean, thoughtful data room signals control. It shows that the founder understands what investors need to believe. It shows that the founder can communicate complexity clearly. It shows that the company is not being held together by personality alone.

A messy data room signals the opposite. It may suggest that the founder has not thought deeply enough about risk, evidence, governance, capital planning, or the investor process.

That may sound harsh, but it is how diligence works.

Investors are not trying to punish founders for missing documents. They are trying to understand whether the company can survive scrutiny. If the founder cannot clearly explain the company inside the data room, the investor has to assume that the same confusion may appear later with customers, regulators, strategic partners, co-investors, or future investors.

That is why the quality of the data room matters.

It is not about administration.

It is about judgment.

Share

The hidden audience inside diligence

One of the biggest mistakes founders make is assuming that the data room is only for the investor they are speaking to.

It is not.

Your data room is also for the people behind that investor.

It is for the associate writing the memo. It is for the partner who was not on the first call. It is for the investment committee. It is for the clinical advisor. It is for the regulatory consultant. It is for the finance team. It is for the legal team. It may also be for co-investors who come into the process later.

This matters because your champion inside the fund cannot carry the whole company alone.

They may like you. They may believe in the opportunity. They may want to move forward. But they still need materials that travel well inside their organisation. They need documents that make the company easier to defend when you are not in the room.

This is the part founders often miss.

A great pitch helps you win attention. A great data room helps your champion win internal support.

If the data room is weak, your champion has to do too much translation. They have to explain the missing context. They have to defend unclear assumptions. They have to connect evidence that should already be connected. They have to answer questions that the data room should have answered before the meeting.

That slows everything down.

Sometimes a deal does not lose momentum because the investor stopped believing. It loses momentum because the internal case becomes too hard to carry.

Your data room should make it easier for someone else to explain why your company matters.

That is the standard.

A better way to think about the data room

The better way to think about a data room is not as a folder structure, but as a diligence journey.

The investor starts with curiosity. Your job is to help them move from curiosity to understanding, from understanding to belief, and from belief to internal conviction.

That does not happen by accident.

It happens when the data room is built around the questions investors actually need answered.

What is the company trying to prove?

Why does the problem matter now?

What evidence supports the solution?

What has been validated already?

What is still unproven?

What risks remain?

Which risks have been reduced?

Who pays?

Who adopts?

Who blocks?

What does this round achieve?

Why does the next milestone change the value of the company?

These questions should shape the way the data room is built. The documents should not sit there waiting to be interpreted. They should help the investor move through the company logically.

This does not mean turning the data room into a sales deck. Investors can see through over-polished storytelling. It means giving structure to the evidence. It means making the company easier to understand. It means helping the investor see where the company is strong, where the company is still early, and why the next stage is worth financing.

That is very different from uploading files.

The best founders do not hide risk

A strong data room does not pretend that the company has no risks.

In health, that would be impossible.

Every health company has risks. The question is whether the founder understands them. Investors do not expect early-stage founders to have every answer. But they do expect founders to know which questions matter.

This is where a thoughtful data room can create real trust.

If regulatory risk exists, explain it clearly. If reimbursement is not solved yet, show the pathway being tested. If clinical evidence is early, explain what has been proven and what the next study needs to demonstrate. If customer adoption is still limited, show what has been learned from early engagement and what must happen for adoption to scale.

Avoiding risk does not make a company look stronger. It makes the founder look less prepared.

The best founders use the data room to show control over uncertainty. They do not claim the path is easy. They show that they understand the path.

That is what investors want to see.

They want to know that the founder can separate belief from evidence. They want to know that the founder understands which assumptions are critical. They want to know that the company has a plan to reduce risk in the right order.

This is one of the biggest differences between a founder who is fundraising reactively and a founder who is building an investable company.

The reactive founder waits for questions.

The investable founder anticipates them.

What this means before you raise

If you are planning to raise, the data room should not be built the night before an investor asks for access.

It should be built before the process begins.

That does not mean every investor should receive the data room immediately. In many cases, founders give access too early. They send too much information before the investor has earned it, before interest is qualified, or before there is a real process. That can also be a mistake.

But being careful with access is not the same as being unprepared.

By the time an investor asks for diligence materials, momentum already exists. You have probably had a conversation. They may have read the deck. They may have asked follow-up questions. They may be considering whether this is worth deeper work.

That is the moment where a strong data room can keep the process moving.

The founder who is prepared can respond quickly, cleanly, and confidently. The founder who is not prepared starts scrambling. Files are outdated. The model needs fixing. Contracts are missing. The cap table is unclear. The regulatory plan is not written down. The clinical evidence is not organised. The use of funds does not match the story.

The investor feels the difference.

Preparedness creates confidence.

Scrambling creates doubt.

This is why founders should build the data room as part of the fundraising strategy, not after the fundraising process has already started.

What Diligence Really Tests

The part founders often miss is that investors are not only reviewing the data room to understand the company. They are also using it to understand how the founder thinks.

That is why diligence materials matter so much.

Read more

Welcome to the latest edition of the HealthVC newsletter. HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions. Today, we are diving deep into one of the most common traps healthtech founders fall into: the strategic partner trap. Understanding this is essential for any founder building in healthcare, because not every impressive logo creates real traction. In this issue, we explore why founders chase strategic partners, why large healthcare organisations often move slower than expected, why partnership conversations can create false confidence, and how investors separate genuine commercial momentum from logo theatre. Whether you are speaking to a pharma company, hospital group, payer, diagnostics company, medtech manufacturer, corporate venture team, or global health platform, this newsletter is your guide to understanding when a strategic partner is valuable, when it is a distraction, and how to avoid spending months chasing a relationship that never becomes a business. Join us as we unpack the strategic partner trap and why founders need to understand the difference between access, validation, and actual commercial proof.

Subscribe now

The logo feels like validation before it proves anything

There is a specific moment in the life of a healthtech startup when the strategic partner trap begins. A large healthcare organisation takes the meeting. It might be a pharma company, a hospital group, a payer, a medtech manufacturer, a diagnostics company, a research institution, or a corporate venture arm. The name is familiar. The brand carries weight. The founder can already imagine what the logo would look like on the traction slide.

The conversation feels serious. The partner asks thoughtful questions, understands the problem, recognises the market shift, and suggests that other internal teams may also be interested. They ask for more information. They request another meeting. They may even talk about a pilot, collaboration, validation study, commercial partnership, or future investment. For a founder, this can feel like the company has crossed an important credibility threshold.

That is where the danger starts, because a strategic partner showing interest is not the same as a strategic partner creating value. Interest can be useful, but it is not revenue, adoption, procurement, distribution, or a repeatable sales motion. It may simply mean that someone inside a large organisation is curious. It may mean they are learning about the market. It may mean they are comparing startups. It may mean they want insight before deciding whether the category matters internally.

This is why founders have to be careful with how they interpret strategic conversations. A large logo can make the company feel more validated than it actually is. It can make the team feel like momentum is building, even when nothing has been bought, implemented, used, or expanded. It can make an investor update sound stronger, even though the relationship has not yet reduced commercial risk.

The logo can open a door, but the door is not the business. The business only becomes real when the relationship converts into commitment, usage, evidence, revenue, or a pathway that makes the next customer easier to win.

The founder sees momentum. The partner may only see exploration.

One of the reasons strategic partnerships are so dangerous is that the relationship often means something very different to each side. For the founder, the strategic partner can feel the company changing. It can feel like the start of distribution, validation, investment, clinical adoption, commercial scale, or even a future exit pathway. The founder sees the relationship as a major opportunity because, for the startup, it is a major opportunity.

Inside the larger organisation, the same relationship may be viewed very differently. It may be part of an innovation scan. It may be one of many startup conversations. It may be useful for market research. It may help an internal team understand a new category. It may be interesting, but not urgent. It may be strategically relevant, but not commercially active. It may have attention, but not budget. It may have curiosity, but not ownership.

This difference matters because startups and large healthcare organisations operate on completely different clocks. The startup is trying to survive, prove the market, raise capital, generate revenue, and create momentum before the runway disappears. The strategic partner is managing internal priorities, budget cycles, procurement rules, legal review, risk committees, compliance teams, clinical stakeholders, IT requirements, and political alignment. The startup feels pressure every week. The large organisation may not feel pressure for months.

That asymmetry is where founders lose time. The founder may be treating the relationship as one of the most important opportunities in the company. The strategic partner may be treating it as an interesting conversation that fits somewhere inside a much larger internal agenda. That does not mean the partner is acting badly. It simply means the founder has to be honest about the level of commitment on the other side.

A warm conversation is not the same as a committed buyer. A thoughtful innovation lead is not the same as a budget owner. A positive meeting is not the same as a procurement path. A future possibility is not the same as a commercial process. This is the distinction founders need to make early, because once the company becomes emotionally attached to the relationship, it becomes much harder to judge it clearly.

The trap is emotional before it becomes commercial

The strategic partner trap works because it gives founders something they badly need: belief. Building in health tech is hard. Sales cycles are slow. Buyers are cautious. Evidence takes time. Regulatory pathways can be complex. Procurement can stretch for months. Fundraising can be brutal when revenue is early and traction is still forming. In that environment, a strategic partner conversation can feel like proof that the market is finally responding.

This is why founders often overvalue these relationships. The partnership gives them a story. It gives them something to say in investor calls. It gives them something to share with advisors. It gives the team a reason to believe that the next stage of the company is coming. It can make the business feel more mature than it actually is.

The danger is that emotional validation can start to replace commercial validation. Instead of asking whether the relationship is moving toward revenue, adoption, evidence, or distribution, the founder starts protecting the possibility. The partner is slow because large companies are slow. The pilot has not started because the right stakeholder is busy. The legal review has not moved because the organisation is complex. The budget has not appeared because the timing is not right yet. The founder keeps waiting because the relationship still feels important.

Sometimes patience is justified. Healthcare does take time. Strategic partners do move slowly. Internal alignment can be complicated. But there is a difference between a slow process that is moving and a warm relationship that is circling. Founders need to know which one they are in.

This is the uncomfortable part of the strategic partner trap. It does not usually feel like failure. It feels like potential. That is why founders can spend months inside it without realising how much time has been lost.

Share

Big logos can hide weak commercial signals

Investors have seen this pattern many times. A founder puts a major healthcare company on the traction slide and talks about the relationship with confidence. The investor asks what the relationship actually means. The founder explains that there have been several meetings, that the partner is very interested, that a pilot has been discussed, that internal teams are being introduced, and that there may be a path to a broader collaboration.

That may sound promising, but investors will usually look past the name and focus on the substance. They want to understand what the relationship proves. Does it prove willingness to pay? Does it prove adoption? Does it prove that procurement can happen? Does it prove the product can survive inside a real healthcare workflow? Does it prove that the buyer has budget, urgency, and ownership? Does it make the next sale easier?

If the relationship does not answer those questions, the logo may not carry as much weight as the founder thinks. A famous name with no contract is not the same as traction. A letter of interest is not the same as revenue. A pilot discussion is not the same as deployment. A partnership announcement is not the same as usage. A corporate innovation meeting is not the same as a commercial buyer with a problem they are ready to solve.

This does not mean strategic partners are useless. They can be extremely valuable when structured properly. They can provide clinical insight, data access, workflow validation, credibility, distribution, reimbursement learning, regulatory perspective, and commercial leverage. But the value is not in the name alone. The value is in the behaviour behind the name.

A small paid pilot with a clear internal owner, defined success metrics, and a realistic path to expansion may be more valuable than a year of vague conversations with a global brand. A narrow deployment with active users may be stronger proof than a press release. A smaller customer that pays, uses the product, gives feedback, and becomes a reference may be more valuable than a strategic partner that keeps asking for another meeting.

Founders often overvalue brand recognition. Investors value proof. That difference matters.

The partnership can quietly start steering the company

One of the hidden risks of the strategic partner trap is that the partner can begin shaping the startup before they have earned the right to do so. This usually happens gradually. The partner asks for a slightly different feature. The founder agrees because the logo matters. The partner wants a specific workflow. The team adjusts the roadmap. The partner asks for a custom integration, extra evidence, a technical review, more documentation, or another internal workshop. None of these requests seems unreasonable on their own, but together they can start pulling the company away from its core market.

This is especially dangerous for early-stage healthtech companies because focus is one of the few advantages they have. A startup cannot afford to build for every possible stakeholder, every possible use case, and every possible enterprise requirement before it has proven a repeatable commercial path. If one strategic partner consumes too much product attention without making a real commitment, the company can drift into a dangerous middle ground. It is no longer building for the market, but it is not yet being paid by the partner shaping the roadmap.

This happens often in healthcare because large organisations are complex. Different teams inside the same organisation may have different views of the problem. The innovation team may want one thing. The clinical team may want another. The commercial team may want something else. The IT team may introduce technical constraints. The legal team may slow the process. The procurement team may arrive late and change the entire conversation.

The founder can end up trying to satisfy an organisation that has not actually decided whether it wants to buy. That is not a strategy. That is drift.

Strategic partners should create leverage, not dependency. If a partner is asking for significant time, custom development, exclusivity, data access, technical work, or roadmap influence, the founder has to understand what the company is receiving in return. A serious commercial commitment may justify the work. A vague future possibility usually does not.

Subscribe now

The best founders qualify strategic partners like customers

Founders are used to being qualified by investors, buyers, and partners, but the best founders also qualify the partner. They do not treat every large logo as automatically worth chasing. They try to understand whether the partner has a real problem, a real internal owner, a real timeline, and a real path to commitment.

This does not mean being arrogant or difficult. It means being disciplined. A founder should want to know who owns the problem inside the organisation, where the budget sits, who would need to approve the project, what would need to happen before implementation, what success would look like, and what happens if the pilot works. If nobody can answer those questions, the founder should be careful about treating the relationship as commercial traction.

A strategic partner can still be useful even if it is not ready to buy. It can be a learning relationship. It can be a market insight relationship. It can be a validation relationship. It can be a future option. But it should be labelled correctly. The mistake is not taking the meeting. The mistake is pretending the meeting proves more than it does.

This level of honesty is important because time is a form of capital. Every month spent chasing a strategic partner is a month not spent closing other customers, improving the product for the real buyer, tightening the sales motion, building repeatable proof, or speaking to investors with clearer traction. The opportunity cost is real, even when the relationship feels exciting.

The best founders look for conversion, not attention. They ask what the relationship becomes. Does it become revenue? Does it become usage? Does it become clinical proof? Does it become a case study? Does it become data access? Does it become distribution? Does it make the next customer easier to win? If the answer is unclear for too long, the founder has to be honest about whether the logo is helping the company or distracting it.

The investor's view is colder than the founder's view

Founders often think investors will be impressed by strategic partner conversations. Sometimes they are, but only when the relationship is specific enough to reduce risk. Investors are not trying to be negative when they ask for details. They are trying to understand whether the partnership is traction or theatre.

This is why vague language can hurt a founder. Saying “we are speaking with a major pharma company” may sound impressive, but it does not explain what has been proven. Saying “we are exploring a partnership with a leading hospital group” may be true, but it does not show whether the buyer has budget, urgency, ownership, or a path to adoption. Saying “we have strong interest from strategic partners” may create excitement, but it does not show whether the company can convert that interest into revenue.

A stronger founder explains the relationship clearly. They explain what is signed, what is verbal, what is exploratory, what is paid, what is unpaid, who owns the relationship, what the next decision is, what the timeline looks like, and what success would unlock. They are not afraid to be precise because precision builds trust.

Investors know that large healthcare organisations can talk to startups for a long time without buying. They know innovation teams can create activity without commercial adoption. They know partnership announcements can look impressive but fail to produce usage. They know founders can become emotionally attached to logos because the fundraising story feels stronger with them included.

The founder who understands this will sound more mature. They will not hide behind the brand. They will explain the substance.

The real lesson

Strategic partners can be powerful, but they can also trap founders inside conversations that never become a business. The trap is confusing access with traction, interest with intent, and logo value with commercial proof.

The goal is not to avoid strategic partners. That would be the wrong lesson. In healthtech, the right strategic partner can help a company move faster, learn faster, validate more deeply, and access parts of the market that would otherwise be hard to reach. The right partner can create evidence, credibility, revenue, distribution, or a real pathway to scale.

But the wrong strategic partner creates the illusion of momentum while quietly consuming time. It gives the founder meetings, encouragement, introductions, and possibility, but not commitment. It can make the company feel busy while the commercial engine remains weak. It can make the fundraising story sound better while the underlying proof remains thin.

Founders need to remember that the market is not validated by who talks to you. It is validated by who commits. A logo may open the door, but only commercial behaviour proves the business.

That is the real lesson of the strategic partner trap. The impressive name is not the milestone. The milestone is what the relationship converts into.

P.S. Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

The Strategic Partner Reality Check

Read more

Welcome to the latest edition of the HealthVC newsletter. HealthVC is the go-to newsletter for founders who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Today, we are diving deep into one of the most overlooked reasons healthtech startups struggle to sell: the invisible implementation cost. Understanding this is essential for any founder building in healthcare, because buyers do not only evaluate whether your product works. They evaluate how much effort, disruption, coordination, risk, and internal work it will take to actually adopt it. In this issue, we explore why implementation is often the hidden reason deals slow down, pilots stall, procurement drags, and interested buyers disappear. Whether you are selling to hospitals, pharma companies, payers, clinics, employers, or care providers, this newsletter is your guide to understanding why healthcare buyers hesitate even when they like the product. Join us as we unpack the invisible implementation cost and why mastering it can completely change how founders sell, scale, and raise capital.

Subscribe now

The product is not the only thing the buyer is evaluating

Most healthtech founders believe the buyer is mainly deciding whether the product is good enough.

That is only partly true.

In reality, the buyer is also deciding whether their organisation can absorb the work required to adopt it. This is where many founders misunderstand healthcare sales. They assume that if the problem is painful, the product is useful, the evidence is strong, and the ROI is clear, the deal should move forward. But healthcare does not work like that.

Healthcare organisations are not clean operating environments waiting for better technology. They are overloaded systems with clinical pressure, regulatory responsibility, staff shortages, legacy infrastructure, internal politics, procurement rules, budget constraints, and deeply embedded workflows. A new product does not enter an empty space. It enters a system that is already full.

That is why a buyer can agree with the founder and still not buy. They can understand the problem and still not move. They can like the demo and still disappear. They can believe the product could help and still delay the decision for months.

The reason is often not a lack of interest.

It is an implementation burden.

The founder sees a product.

The buyer sees a project.

That gap is the invisible implementation cost.

Implementation is not onboarding

Most startups describe implementation as onboarding.

They think it means setting up the account, training the customer, connecting the system, and getting the first users live. But in healthtech, implementation is much bigger than onboarding. It is the total organisational burden created by adopting the product before the product creates value.

It is the internal meetings. It is the IT review. It is the clinical workflow change. It is the procurement process. It is the data governance discussion. It is the security questionnaire. It is the training burden. It is the staff communication. It is the change management. It is the political risk for the internal champion. It is the question of who owns the product after the contract is signed.

This cost is often invisible to the founder because it does not sit inside the product.

It sits inside the customer.

That is why so many founders misread buyer behaviour. They think silence means the buyer was not serious. They think delays mean the procurement team is slow. They think a lack of usage means the customer is lazy. Sometimes that may be true. But very often, the real issue is that the startup has created more internal work than the buyer is able or willing to carry.

Healthcare buyers are not only buying software, devices, diagnostics, analytics, workflow tools, patient engagement platforms, or AI systems. They are buying the operational reality that comes with them.

Every value proposition has an implementation shadow

A founder may say, “We reduce clinician workload.”

The buyer hears, “Which clinician has to change their current workflow first?”

A founder may say, “We integrate with existing systems.”

The buyer hears, “How much IT time will this take, and who is going to approve it?”

A founder may say, “The dashboard gives leadership better visibility.”

The buyer hears, “Who will actually look at this, who will act on the data, and what happens if nobody owns it?”

A founder may say, “Patients can use this from home.”

The buyer hears, “Who explains this to patients, who follows up when they do not engage, and who handles the exceptions?”

This is the reality of healthtech adoption. Every value proposition has an implementation shadow. The stronger the founder, the more clearly they understand that shadow.

The mistake many founders make is that they sell the future state without explaining the transition state. They sell the world after the product has been adopted. They show the efficiency, the savings, the better patient experience, the improved data, the faster triage, the cleaner workflow, the reduced admin burden, or the stronger clinical outcomes.

But the buyer is living in the present state.

They are asking how to get from where they are today to the future the founder is describing.

That journey is where deals slow down.

Leave a comment

The buyer has to survive the transition

The buyer may believe the future state is better.

But if the transition looks painful, unclear, risky, or politically difficult, they may choose to stay with the status quo. Not because the status quo is good, but because the status quo is known.

In healthcare, known pain often beats unknown complexity.

This is one of the most frustrating lessons for founders. Being better is not enough. Being adoptable matters just as much. A healthtech company can have a better product and still lose to inertia. It can have a stronger clinical case and still lose to internal complexity. It can have a convincing ROI model and still lose because nobody inside the organisation has the bandwidth to implement it.

That is why founder-led selling in healthcare has to go beyond persuasion.

It has to reduce the buyer’s perceived operational risk.

A serious buyer does not only want to know why your product matters. They want to know what it will take to make it work inside their organisation. They want to know who needs to be involved. They want to know how long it will take. They want to know what resources are required. They want to know what could go wrong. They want to know what has gone wrong with similar customers. They want to know what the first thirty, sixty, and ninety days look like. They want to know whether your team has done this before.

This is why saying “implementation is easy” is often weak.

Buyers do not want vague reassurance.

They want operational confidence.

The strongest founders sell the path, not just the product

The founder who says “we are easy to implement” sounds like they are trying to remove concern.

The founder who explains the implementation pathway sounds like they understand the buyer.

There is a big difference.

The best healthtech founders do not pretend there is no implementation burden. They map it. They explain it. They reduce it. They show the buyer what has to happen, who has to be involved, what the startup will own, what the customer needs to prepare, and how success will be measured.

They turn implementation from an unknown risk into a managed process.

That is where trust starts to build.

Trust in healthtech does not come only from evidence. It comes from the buyer believing that the founder understands the operating environment. It comes from the founder showing that they know how healthcare organisations actually behave. It comes from proving that the product is not just impressive, but deployable.

The better founder does not only sell the clinical case.

They sell the operational path.

Why this matters to investors

This matters deeply for fundraising.

Investors do not only want to know whether customers like the product. They want to know whether customers can adopt it repeatedly without the company breaking under the weight of implementation.

A startup can have exciting pilots and still be hard to scale if every customer requires a different onboarding process, different integration work, different training materials, different success metrics, and heavy founder involvement.

That is when a company starts to look less like software and more like a services business.

This is one of the hidden reasons investors dig into the quality of revenue. They are not only looking at logos. They are looking at whether those logos are live, active, expanding, renewing, and producing repeatable evidence. They want to understand how long it takes to go from a signed agreement to active usage. They want to understand how much hand-holding is required. They want to understand whether customer success is scalable. They want to understand whether implementation improves over time or becomes more complex with each new customer.

A founder may say, “We have five hospital pilots.”

An investor may ask, “How many are live?”

A founder may say, “We signed a strategic partnership.”

An investor may ask, “What is actually being used?”

A founder may say, “The buyer loved the product.”

An investor may ask, “Who owns implementation inside the customer?”

A founder may say, “We are expanding across the system.”

An investor may ask, “What evidence shows this can be repeated with the next customer?”

This is why implementation is not only a sales problem. It is a company building problem. It affects sales cycle length, gross margin, customer success, retention, expansion, working capital, founder capacity, and investor confidence.

The implementation cost eventually appears in the numbers

The invisible implementation cost often shows up later in the metrics.

It appears as delayed revenue recognition. It appears as pilots that never convert. It appears as low usage after signing. It appears as customer success teams are becoming overloaded. It appears as sales cycles that keep stretching. It appears as founders are spending too much time saving accounts instead of building the company. It appears as an impressive pipeline but weak conversion.

By the time it appears in the metrics, the root cause has usually been present for months.

The company did not make adoption easy enough.

This is why the best founders think about implementation before the buyer asks. They do not wait until procurement to discover the blockers. They do not wait until after signing to figure out internal ownership. They do not wait until onboarding to realise the workflow is more complicated than expected.

They design the adoption path as part of the commercial strategy.

That means the sales process should not only qualify the budget and need. It should qualify for implementation capacity. Can this organisation actually adopt the product now? Who has to approve it? Who has to use it? Who has to support it? Who has to defend it internally? What workflow has to change? What does the buyer need before launch? Who owns success after launch? What would make this fail even if the product works?

These are not minor details.

They are the difference between interest and adoption.

Make the first step smaller

A founder who understands this sells differently.

They stop treating implementation as something that happens after the sale. They bring implementation into the sale itself. They show the buyer what the first use case should be. They make the first step smaller. They define the internal owner. They make the success metric simple. They reduce the number of stakeholders needed for the first deployment. They give the champion materials to sell internally. They make the buyer feel that adoption is not another major transformation project.

This is especially important in healthcare because many buyers have been burned before.

They have seen pilots that went nowhere. They have seen platforms that required too much training. They have seen integrations that dragged on for months. They have seen products that leadership liked but frontline teams ignored. They have seen vendors disappear after signing. They have seen tools that created more admin work than they removed.

So when a new founder arrives with another promising solution, the buyer is not starting from a neutral position.

They are carrying the memory of previous implementation pain.

That is why founders need to make the change feel smaller.

Not the ambition.

The change.

The biggest vision can still be there. The founder can still build toward a platform, a category, or a system-level transformation. But the first step for the buyer has to feel manageable. The buyer needs to see a narrow entry point, a clear owner, a simple workflow, a fast proof point, and a realistic adoption path.

The stronger founder does not try to sell the entire transformation on day one.

They sell the first piece of the transformation that the buyer can actually absorb.

The real lesson

Your buyer may believe in the destination.

But they still need confidence in the journey.

The real question is not only, “Does this product create value?”

The real question is, “Can this organisation reach that value without creating too much pain along the way?”

That is the invisible implementation cost.

And for many startups, it is the reason the deal does not move.

The founder thinks the buyer is evaluating innovation. The buyer is evaluating effort. The founder thinks the buyer is comparing solutions. The buyer is comparing disruption. The founder thinks the buyer is deciding whether the product is useful. The buyer is deciding whether the organisation has the capacity to change.

Once founders understand this, the sales conversation improves.

They stop over relying on the demo. They stop assuming ROI will carry the deal. They stop confusing interest with readiness. They stop treating implementation as a post-sale function. They start building the adoption case as carefully as they build the product case.

That is when healthtech companies become easier to buy.

And in healthcare, being easier to buy is a serious competitive advantage.

How to audit your invisible implementation cost

Read more

Welcome back to HealthVC, the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Every week, we break down how health, life sciences, and venture capital really work. Not the version founders hear on panels. Not the version investors put into polished LinkedIn posts. The real version. The version that decides whether a company gets funded, whether a pilot becomes revenue, whether a hospital actually adopts a product, and whether a founder can turn a promising idea into a serious company.

Today, I want to talk about something most founders know matters, but very few build deliberately.

Trust.

Every week, I speak with founders who are building something that looks valuable on paper. The problem is real. The market is large. The clinical pain point is obvious. The product has potential. The founder is credible. The deck looks good. The early conversations sound positive. Doctors say the product is interesting. Investors ask for a second call. Hospitals want to keep talking. Strategic partners say there could be a fit.

And still, the company does not move.

The hospital asks for another meeting. The investor wants more proof. The clinical lead likes the product but cannot get internal approval. The pharma company says the timing is not right. The payer wants more evidence. The buyer wants to know who else is using it. Procurement wants more documentation. Legal wants to review the risk. IT wants to understand the data flow. The founder leaves every conversation thinking the same thing. They understand the problem, so why are they not moving?

This is one of the most misunderstood parts of building in healthcare.

In most markets, the early question is relatively simple. Does the product solve a painful problem? In healthcare, that is only the beginning. A product can solve a painful problem and still fail to be adopted because the system does not yet trust the company enough to let it in.

That is the part that founders underestimate.

Healthcare does not reward novelty in the same way consumer software or general enterprise software does. Healthcare is not designed to move quickly just because something is better. It is designed to protect patients, reduce liability, preserve clinical workflows, manage budgets, satisfy regulators, avoid reputational damage, and prevent unnecessary risk from entering the system.

That does not mean healthcare does not need innovation. It clearly does.

It means innovation has to earn permission.

This is why health startups need a trust strategy.

Not a brand strategy. Not a communications strategy. Not a few advisor logos. Not a professor on the deck. Not a hospital name in the pipeline. Not a friendly quote from a doctor. A real trust strategy.

A trust strategy is the deliberate process of building the evidence, governance, relationships, documentation, communication, and operational maturity that makes customers, investors, clinicians, regulators, and partners believe your company is safe enough, serious enough, and credible enough to work with.

Most founders think trust comes after traction.

In healthcare, trust often has to come before traction.

Subscribe now

The first mistake founders make is confusing reputation with trust

A lot of early health founders think they are building trust because respected people are around the company. They have a professor on the advisory board. They have a hospital pilot. They have a pharma conversation. They have a former executive helping informally. They have a university affiliation. They have a grant. They have been invited to speak at a conference. A few respected clinicians have told them the idea is interesting.

All of that helps.

But none of it is the same as trust.

Reputation gets you the meeting. Trust gets you the decision.

This distinction matters because founders often mistake access for progress. A respected advisor can open a door, but they do not make the product safe to adopt. A hospital pilot can make the deck look stronger, but it does not prove the product can survive procurement, implementation, workflow integration, clinical responsibility, data protection review, and budget approval. A pharma conversation can sound strategic, but it does not mean the startup has built enough credibility to become a real partner.

In healthcare, people may like you before they trust you.

They may believe the problem is important before they trust your solution. They may believe the science is promising before they trust the company. They may believe the founder is smart before they trust the execution. They may believe the product works in a narrow setting before they trust it across a wider system.

Founders need to understand the gap between interest and trust.

Interest sounds like, “This is exciting.”

Trust sounds like, “We are willing to put our name, budget, workflow, patients, data, reputation, or capital behind this.”

That is a very different threshold.

Healthcare buyers are not only buying the product. They are buying the risk of adopting it

This is where many founders misunderstand the customer.

A founder sees the product through the lens of value. The buyer sees the product through the lens of risk. The founder says the product can improve outcomes, reduce workload, lower cost, increase access, speed up diagnosis, support better decisions, or make care delivery more efficient. The buyer is often thinking about something else entirely.

What happens if this fails? Who is responsible? How hard is this to implement? Who owns the data? What will clinicians need to change? Will this create legal exposure? Will it affect patient safety? Will it survive an audit? Will staff actually use it? Will the startup still exist in two years? Will this become another tool that creates work rather than removes it?

The founder is selling upside.

The healthcare system is calculating downside.

That does not mean buyers are irrational. It means they operate inside a risk environment that founders need to understand. In healthcare, a bad product decision can affect patients, clinicians, budgets, compliance, data privacy, reimbursement, internal politics, and public reputation. Nobody wants to be the person who approved a startup that later creates clinical, operational, or reputational problems.

This is why healthcare adoption can feel painfully slow, even when the product is good.

The system is not only asking whether the solution works. It is asking whether the company can be trusted with the consequences of being adopted.

For founders, this changes the job. You are not just trying to prove that your product has value. You are trying to reduce the perceived risk of believing you.

That means trust has to be designed into the company from the beginning.

Trust is built through evidence, not enthusiasm

Early enthusiasm is useful, but it is not enough.

A clinician saying the product is interesting is not clinical proof. A pilot conversation is not implementation validation. A letter of intent is not revenue. A grant is not market demand. A dataset is not reproducible evidence. A strong demo is not a scalable workflow. A meeting with a strategic partner is not commercial traction.

Founders need to become much more disciplined in how they build and present evidence.

In healthcare, evidence is not just something you collect for investors. It is the foundation of trust across every important stakeholder. Investors need evidence that risk is being reduced. Clinicians need evidence that the product is safe, useful, and relevant. Buyers need evidence that adoption will not create more problems than it solves. Payers need evidence that value can be measured. Regulators need evidence that claims are appropriate. Strategic partners need evidence that the company is mature enough to work with.

The problem is that many founders collect evidence randomly.

They run a pilot because someone offered one. They gather testimonials because they sound good. They add user quotes to the deck. They publish early data without thinking about what question it answers. They say they are building evidence, but they have not defined the trust gap they are trying to close.

That is the wrong approach.

A strong health founder asks a better question.

What does each stakeholder need to believe before they can move forward?

That question changes everything.

If the investor does not trust the market, you need evidence of buyer urgency. If the buyer does not trust implementation, you need evidence that the product can be adopted without disrupting the system. If clinicians do not trust safety, you need evidence around clinical governance, oversight, and risk boundaries. If payers do not trust economic value, you need evidence that connects outcomes to cost. If pharma does not trust the platform, you need evidence of reproducibility, data quality, and strategic relevance.

Evidence is not a pile of proof.

Evidence is a sequence of trust-building.

Share

The strongest founders make trust travel inside the organisation

This is a major point that early founders often miss.

In healthcare, the person who likes your product often has to convince many other people before anything happens. A clinician may need to convince a department head. A department head may need to convince procurement. Procurement may need to involve legal. Legal may need to involve compliance. Compliance may need to involve data protection. Data protection may need to involve IT. IT may need to involve security. Finance may need to approve the budget. A senior executive may need to accept the reputational risk.

The founder is not only selling to one person.

The founder is equipping one person to sell internally.

This is why trust assets matter.

A trust asset is anything that helps your champion defend the decision to work with you when you are not in the room. This can include a clear evidence summary, an implementation plan, a security overview, a clinical governance summary, a regulatory position, a reference customer, a risk assessment, a health economics argument, a procurement pack, a product claims document, or a simple board-ready explanation of why the company is credible.

Most founders give their champions a deck.

Better founders give their champions the material they need to win the internal argument.

This is one reason founders lose deals they thought were progressing well. The meeting went well, the user was excited, and the founder assumed momentum would continue. But inside the organisation, the champion could not answer the harder questions. They could not explain the implementation burden. They could not defend the regulatory position. They could not show enough evidence. They could not prove budget relevance. They could not convince others that the startup was mature enough.

The deal did not die because the product lacked value.

It died because trust could not travel through the organisation.

That is a powerful lesson for founders.

If your trust only exists when you are in the room, it is not strong enough yet.

Investors also underwrite trust

Founders often think investors are only judging the market, team, technology, and traction.

They are also judging trust.

Can this founder be trusted to understand the complexity of the market? Can they be trusted to communicate what is known and unknown? Can they be trusted to manage clinical, regulatory, and commercial risk? Can they be trusted in front of hospitals, pharma partners, payers, and future investors? Can they be trusted to build a company, not just a product?

This is especially important in healthcare because investors know that shortcuts are expensive.

A vague regulatory answer is not a small issue. It may become a financing issue. Weak data governance is not an admin problem. It may block partnerships. Poor documentation is not paperwork. It may create diligence problems. Overclaiming the product is not confidence. It may create regulatory and reputational risk. A founder who cannot clearly explain what still needs to be proven is not being ambitious. They are making the investor nervous.

The best health founders do not pretend that risk does not exist.

They show that they know how to manage it.

That is what builds investor trust.

There is a big difference between a founder who says there is no regulatory risk and a founder who says they understand the likely regulatory pathway, they have validated certain assumptions, they still need to clarify others, they have the right advisors involved, and they know how this affects the next financing milestone.

The second founder sounds more credible because they are not hiding complexity. They are controlling it.

Healthcare investors do not expect early companies to have everything solved. But they do expect founders to know which risks matter, which risks are unresolved, and what the plan is to reduce them.

That is trust.

Trust breaks when founders overclaim

One of the fastest ways to lose trust in healthcare is to overclaim.

Founders do this all the time, often without meaning to. They say the product is clinically validated when it has only been tested in a limited setting. They say hospitals are customers when they are unpaid pilots. They say pharma is interested when they have only had early conversations. They say the platform is scalable when implementation is still manual. They say the AI improves outcomes when the evidence only shows workflow improvement. They say the product is regulatory-ready when classification is still unclear.

These statements may make the company sound stronger in the short term.

But they create doubt in the long term.

In healthcare, sophisticated investors, clinicians, and buyers are trained to notice the gap between claim and proof. When the claim is bigger than the evidence, the founder loses credibility. Once that happens, every other part of the story becomes harder to believe.

This is why disciplined language matters.

The strongest founders are precise. They separate what has been proven from what is being tested. They separate clinical feedback from clinical validation. They separate pipeline from revenue. They separate product capability from measured outcome. They separate regulatory assumptions from regulatory confirmation. They separate market interest from buying intent.

That precision does not weaken the story.

It strengthens it.

A founder who is clear about the current state of evidence sounds more investable than a founder who tries to make everything look complete. Serious people do not need perfection. They need clarity.

In healthcare, clarity is a trust signal.

Trust is operational

Trust is not only built in the deck. It is built in how the company behaves.

Do you follow up with clear materials? Do you document decisions? Do you know your regulatory position? Do you understand data protection? Do you have a basic quality process? Do you respond to diligence questions properly? Do you know who owns clinical risk? Do you communicate consistently with partners? Do you make it easy for customers to understand what happens after they say yes?

These things may feel boring to a founder who wants to talk about vision.

But in healthcare, operational maturity is part of the sale.

A buyer is not only asking whether the product works. They are asking whether the company can support them after adoption. An investor is not only asking whether the market is large. They are asking whether the founder can manage a complex path. A strategic partner is not only asking whether the technology is interesting. They are asking whether the startup will be a reliable partner.

This is where many startups unintentionally look immature.

They have the science, but not the process. They have the product, but not the documentation. They have the meetings, but not the follow-through. They have the vision, but not the operating discipline. They have the founder charisma, but not the institutional readiness.

In healthcare, this matters earlier than founders expect.

You do not need to look like a large company. But you do need to look like a company that understands the environment it is entering.

That is the difference.

The real lesson

Healthcare does not adopt innovation simply because it is needed.

It adopts innovation when enough people inside the system trust that the innovation is safe, credible, useful, defensible, and worth the disruption.

That is why founders need to stop treating trust as something soft.

Trust is not soft.

Trust affects sales cycles. Trust affects investor appetite. Trust affects pricing power. Trust affects partnership quality. Trust affects regulatory confidence. Trust affects whether a champion can convince their organisation to move. Trust affects whether a pilot converts. Trust affects whether a company survives diligence.

For health startups, trust is not a marketing layer added after the product is built.

It is part of the product. It is part of the commercial strategy. It is part of the fundraising strategy. It is part of the company’s infrastructure.

The founders who understand this build differently. They do not just ask how to get more meetings. They ask what people need to believe before they can take the next step. They do not just collect logos. They build proof. They do not just chase interest. They reduce uncertainty. They do not just pitch the upside. They make the risk easier to understand.

That is what makes the market move.

Not louder marketing.

Deeper trust.

P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Subscribe now and operate like a pro.

Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

The HealthVC Trust Strategy Framework

Read more